  
This document may not be shown to any unauthorized person without the express permission of Sponsor.                                                                Page i of 70  
 Self-Fitting  (SF) Strategy Validation  
NSR  Device  Study  Protocol : SF Study  
Protocol Number: D00232675  
National Clinical Trial (NCT) Identified Number:  04972162  
Principal Investigator:  Lindsey Jorgensen, Ph.D., Au.D.  
NSR Device  Sponsor: WSAUD A/S  
Funded by : NSR Device Sponsor  
FINAL Version Number:  v. 1.1 
08 September  2021 
 
Summary of Changes  from Previous Version  1.0 dated 25 May 2021 : 
Affected 
Section(s)  Summary of Revisions Made  Rationale  
Title Page  Updated NCT Identified Number  to: 04972162  Received it after IRB approval of the study  
Title Page  Updated FINAL Version Number and Date  to: v. 
1.1 and 08 September 2021  Updated due to minor protocol amendment  
All Headers  Updated Version Number and Date  to: 1.1 and 
08 September 2021  Updated due to minor protocol amendment  
9.4.2.1  Corrected  (i.e., yellow highlighted parts)  
weighted harmonic mean (WHM) formula  to 
show the WHM of a set of p -values is the 
reciprocal of the WHM of the reciprocals of 
these p -valu es. 
pWHM = ∑ wi / ∑ (wi / pi)        i=1….L  While typing the formula, typing errors 
occurred  
9.4.2.1  Corrected to L=3 Typing error occurred  
9.4.2.1  Added : The weights (w i ) are set equal to 
0.3333…  We weight them equally because the 
scores are calculated with each component 
weighted equally.  Specify how the three p -values will be 
weighted.  
This confidential document is the property of SPONSOR. The protocol must be kept in a confidential manner and 
only be used in connection with the investigation. No unpublished information contained herein may be disclosed 
without prior written approval of SPONSOR.  
  
This document may not be shown to any unauthorized person without the express permission of Sponsor.                                                                Page ii of 70  
  
Table of Contents  
STATEMENT OF COMPLIANCE  ................................ ................................ ................................ .............................  5 
1 PROTOCOL SUMMARY  ................................ ................................ ................................ ...............................  5 
1.1 Synopsis  ................................ ................................ ................................ ................................ ................  5 
1.2 Schema  ................................ ................................ ................................ ................................ .................  9 
2 INTRODUCTION  ................................ ................................ ................................ ................................ ..........  12 
2.1 Study Rationale  ................................ ................................ ................................ ................................ .. 12 
2.2 Background ................................ ................................ ................................ ................................ .........  12 
2.3 Risk/Benefit Assessment  ................................ ................................ ................................ ..................  12 
2.3.1  Known Potential Risks  ................................ ................................ ................................ ... 12 
2.3.2  Known Potential Benefits  ................................ ................................ ..............................  14 
2.3.3  Assessment of Potential Risks and Benefits  ................................ ..............................  15 
3 OBJECTIVES AND ENDPOINTS  ................................ ................................ ................................ ..............  15 
4 STUDY DESIGN  ................................ ................................ ................................ ................................ ...........  19 
4.1 Overall Design  ................................ ................................ ................................ ................................ .... 19 
4.2 Scientific Rationale for Study Design ................................ ................................ ..............................  20 
4.3 End of Study Definition  ................................ ................................ ................................ .....................  21 
5 STUD Y POPULATION  ................................ ................................ ................................ ................................  21 
5.1 Inclusion Criteria  ................................ ................................ ................................ ................................  21 
5.2 Exclusion Criteria  ................................ ................................ ................................ ...............................  22 
5.3 Screen Failures  ................................ ................................ ................................ ................................ .. 22 
5.4 Strategies  for Recruitment and Retention  ................................ ................................ ......................  23 
6 STUDY INTERVENTION  ................................ ................................ ................................ ............................  24 
6.1 Study Intervention(s) Administration  ................................ ................................ ...............................  24 
6.1.1  Study Intervention Description  ................................ ................................ .....................  24 
6.1.2  Nonsignificant risk determination  ................................ ................................ .................  26 
6.1.3  inventory and dispensing  ................................ ................................ ..............................  27 
6.2 Preparation/Handling/Storage/Accountability  ................................ ................................ ................  27 
6.2.1  Acquisition and accountability  ................................ ................................ ......................  27 
6.2.2  Formulation, Appearance, Packaging, and Labeling  ................................ ................  27 
6.2.3  Product Storage and Stability  ................................ ................................ .......................  29 
6.2.4  Preparation  ................................ ................................ ................................ ......................  29 
6.3 Measures to Minimize Bias: RANDOMIZED TREATMENT ORDER and Blinding  ..................  29 
6.4 Study Intervention Compliance  ................................ ................................ ................................ ........  30 
7 STUDY INTERVENTION DISCONTINUATION AND SUBJECT 
DISCONTIN UATION/WITHDRAWAL  ................................ ................................ ................................ ....................  30 
7.1 Discontinuation of Study Intervention  ................................ ................................ .............................  30 
7.2 Subject Discontinuation/Withdrawal from the Study  ................................ ................................ ..... 30 
7.3 Lost to Follow -Up ................................ ................................ ................................ ...............................  31 
8 STUDY ASSESSMENTS AND PROCEDURES  ................................ ................................ .....................  31 
8.1 Effectiveness Assessments  ................................ ................................ ................................ .............  31 
8.1.1  Screening  ................................ ................................ ................................ ........................  34 
8.1.2  Visit 1  34 
8.1.3  Field Test 1  ................................ ................................ ................................ .....................  35 
8.1.4  Visit 2  36 
  
This document may not be shown to any unauthorized person without the express permission of Sponsor.                                                                Page iii of 70  
 8.1.5  Washout Period  (only for CRoss -Over Design)  ................................ .........................  37 
8.1.6  Field Test 2 (only For Cross -Over Design)  ................................ ................................  37 
8.1.7  Visit 3 (only For Cross -Over Design)  ................................ ................................ ..........  37 
8.2 Safety and Other Assessments  ................................ ................................ ................................ .......  37 
8.3 Adverse Events and Serious Adverse Events  ................................ ................................ ...............  38 
8.3.1  Definition of Adverse Events (AE)  ................................ ................................ ...............  38 
8.3.2  Definition of Serious Adverse Events (SAE)  ................................ ..............................  38 
8.3.3  Classification of an Adverse Event  ................................ ................................ ..............  39 
8.3.4  Time Period and Frequency for Event Assessment and Follow -Up .......................  39 
8.3.5  Adverse Event Reporting  ................................ ................................ ..............................  40 
8.3.6  Serious Adverse Event Reporting  ................................ ................................ ...............  40 
8.4 Unanticipated Problems  ................................ ................................ ................................ ....................  40 
8.4.1  Definition of Unanticipated Problems (UP)  ................................ ................................ . 41 
8.4.2  Unanticipated Problem Reporting  ................................ ................................ ................  41 
8.4.3  Reporting Unanticipated Problems to Subjects  ................................ .........................  41 
9 STATISTICAL CONSIDERATIONS  ................................ ................................ ................................ ..........  41 
9.1 Statistical Hypotheses  ................................ ................................ ................................ .......................  41 
9.1.1  PRIMARY  ................................ ................................ ................................ ........................  41 
9.1.2  secondary  ................................ ................................ ................................ ........................  42 
9.2 Sample Size De termination  ................................ ................................ ................................ ..............  43 
9.3 Populations for Analyses  ................................ ................................ ................................ ..................  45 
9.4 Statistical Analyses ................................ ................................ ................................ ............................  45 
9.4.1  General Approach  ................................ ................................ ................................ ..........  45 
9.4.2  Analysis of the primary Effectiveness Endpoint  ................................ ........................  47 
9.4.3  Analysis of the Secondary Endpoints  ................................ ................................ .........  50 
9.4.4  Safety Analyses  ................................ ................................ ................................ ..............  51 
9.4.5  Baseline Descriptive Statistics  ................................ ................................ .....................  51 
9.4.6  Planned Interim Analyses  ................................ ................................ .............................  51 
9.4.7  Sub-Group Analyses  ................................ ................................ ................................ ..... 51 
9.4.8  Tabulation of Individual subject Data  ................................ ................................ ..........  51 
10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  ..............................  51 
10.1  Regulatory, Ethical, and Study Oversight Considerations  ................................ ...........................  51 
10.1.1  Informed Consent Process  ................................ ................................ ...........................  51 
10.1.2  Study Discontinuation and Closure  ................................ ................................ .............  53 
10.1.3  Confidentiality and Privacy  ................................ ................................ ...........................  53 
10.1.4  Key Roles and Study Governance  ................................ ................................ ..............  54 
10.1.5  Safety Oversight  ................................ ................................ ................................ .............  54 
10.1.6  Clinical Monitoring  ................................ ................................ ................................ ..........  54 
10.1.7  Quality Assurance and Quality Control  ................................ ................................ .......  55 
10.1.8  Data Handling and Record Keeping  ................................ ................................ ............  57 
10.1.9  Protocol Deviations  ................................ ................................ ................................ ........  59 
10.1.10  Conflict of Interest Policy  ................................ ................................ ..............................  59 
10.2  Additional Considerations  ................................ ................................ ................................ .................  59 
10.3 Abbreviations  ................................ ................................ ................................ ................................ ...... 61 
10.4  Protocol Amendment History  ................................ ................................ ................................ ...........  61 
11 References  ................................ ................................ ................................ ................................ ....................  63 
  
This document may not be shown to any unauthorized person without the express permission of Sponsor.                                                                Page iv of 70  
 12 APPENDIX I Nonsignificant Risk Determination ................................ ................................ ......................  65 
13 APPENDIX II Device Labeling  ................................ ................................ ................................ ....................  70 
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of Sponsor.                                                                Page 5 of 70  STATEMENT OF COMPLIANCE  
 
This non-significant risk ( NSR) device study  will be carried out  in accordance with  Clinical Investigation of 
Medical Devices for Human Subjects – Good Clinical Practice  (ISO 14155  Third edition 2020 -07) and the 
following:  
• United States (US) Code of Federal Regulations (CFR) applicable to NSR device studies (21 CFR Par t 50, 
21 CFR Part 56, 21 CFR Part 812.2(b))  
 
The protocol, informed consent form  (ICF), recruitment materials, and all subject  materials will be 
submitted to the Institutional Review Board (IRB) for review and approval.  Approval of both the protocol 
and t he consent form must be obtained before any subject  is enrolled.  Any amendment to the protocol 
will require review and approval by the IRB before the changes are implemented to the study.  In addition, 
all changes to the consent form will be IRB -approved;  a determination will be made regarding whether a 
new consent needs to be obtained from subject s who provided consent using a previously approved 
consent form . 
 
1  PROTOCOL SUMMARY  
1.1 SYNOPSIS  
Title:  Self-Fitting  (SF) Strategy Validation NSR Device Study  Protocol : SF Study  
  
Study Des cription : A prospective, randomized  controlled,  adaptive  design , non-inferiority,  
pre-market  and NSR device study. To be conducted in a minimum of 28 
adult subject s with mild -to-moderate hearing loss to validate the 
effectiveness of the Vibe  SF strategy . Validation measures subject ´s 
perceived hearing aid benefit when using the Vibe  SF self-fit hearing aids 
and when using  Silk 1X  Hearing Care Professional (HCP) fit hearing aids.  
 
The study begins with a cross -over design. At the interim analysis, the 
possibility of an interaction  effect is evaluated through a nuisance 
parameter. If it is determined to be likely, the design is switched to a 
parallel -group design with a larger sample size. Only data from the first 
period will be included from those subject s who early on participated in 
the cross -over design.  
 
The Silk 1X HCP fit  hearing ai ds are fitted to National Acoustic Labo ratories 
Nonl inear Version 2 (NAL -NL2) prescriptive targets, verified by probe -mic 
real-ear measures (REM). The null hypothesis  (H0) is that subject ´s 
perceived hearing aid s benefit using Vibe  SF hearing aids is inferior to Silk 
1X HCP fit  hearing aids, and the alternative hypothesis  (Ha) is that subject ´s 
perceived hearing aids benefit using Vibe  SF hearing aids is non -inferior to  
that using  Silk 1X HCP fit  hearing aids.  
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of Sponsor.                                                                Page 6 of 70    
Description of Study 
Intervention:  The mechanism for validating the Vibe SF  strategy will be to compare 
subject ´s perceived hearing aid benefit after two 14 days series of using 
Vibe SF/Silk 1X HCP fit  hearing aids.          
  
Objectives:  
 Primary Effectiveness Objective:   
To demonstrate that the  Vibe SF strategy is non -inferior to the HCP fit  
strategy  in subject ´s perceived hearing aid benefit after using  the Vibe  SF 
and Silk 1X HCP fit  hearing aids in real-life conditions.  
  
 Secondary Hearing Aid Benefit Objectives:  
To score  each of the following hearing aid benefit performance measures 
when the subject  is using the Vibe  SF and Silk 1X HCP fit  hearing aid s: 
1. Sound quality,  speech understanding  and hearing aid  
satisfaction real-time assessment , 
2. Speech -in-noise recognition performance , and 
3. Hearing disability in communication situations . 
 
Secondary Gain Selection Objective:  
Individual f requency -specific real-ear gain comparison of the two different 
fittin g strategies ( Vibe SF and HCP fit ).  
 
Secondary Preference Objective:  
Fitting  strategy  (Vibe SF or HCP fit ) preference  reported by the subject .  
 
Secondary Safety Objective:  
To estimate the rate of adverse device e ffects  (ADEs)  when the subject  is 
using the Vibe  SF hearing aid s.  
  
Endpoint s: Primary  Effectiveness  Endpoint:    
Differences in the benefit scores on each of the three communication 
subscales  as captured by the Abbreviated Profile of Hearing Aid Benefit 
(APHAB)  after wearing each Vibe SF/ Silk 1X HCP fit  hearing aids for 14 
days . For each subject , the endpoints are the individual 3 communication 
subscale differences between the HCP fit  subscal e (benefit) score and SF 
subscale (benefit) score:  
• ∆EC(benefit) HCP fit  - ∆EC(benefit) SF  
• ∆BN(benefit) HCP fit  - ∆BN(benefit) SF  
• ∆RV(benefit) HCP fi t - ∆RV(benefit) SF 
 
Secondary Hearing Aid Benefit Endpoints:  
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of Sponsor.                                                                Page 7 of 70  1. The subject ´s sound quali ty, speech understanding  and 
hearing aid  satisfaction Ecological Momentary Assess ment 
(EMA) ratings measured repeatedly under real -life conditions,  
2. Speech -in-noise recognition performance as measured by the 
Quick Speech -In-Noise test (QuickSIN) ,  
3. Hearing disability resulting from hearing loss quantified by the 
short form of the Speech, Spatial, and Qualities of Hearing 
Scale for clinical use:  the SSQ -12 questionnaire.  
 
Secondary Gain Selection Endpoint:  
Individual frequency -specific gain comparis on for the two different fitting 
strategies  (Vibe SF and HCP fit ) for each ear as measured with probe -mic 
real-ear measures (REM).  
 
Secondary Preference Endpoint:  
Fitting preference Vibe SF or HCP  fit strategy . Subject s are asked which of 
the hearing aids they would prefer to keep using a 5-point  Likert scale.  
 
Secondary Safety Endpoint:  
The number of adverse device  effects ( ADEs ) in the time period when the 
subject  is using the Vibe  SF hearing aids.  
  
Population:  A minimum of 28 US subject s, within the age  of 18 years and older, 
inexperienced or experienced hearing aid users with perceived mild -to-
moderate hearing impairment .  Potential subject s will be screened to 
confirm their  bilateral sensorineural hearing loss.  
  
Description of 
Sites /Facilities  Enrolling 
Subject s: A single  US University hearing aid research clinic. Potential subject s will be 
recruited locally by outreach at the investigator sites, local 
advertisements, social media advertisements and if needed professional 
recruiting service.  
  
Study Duration : Adaptive Design:  IF no significant Interaction Effect  
28 Subjects : Cross-over design  
Enrollment (Visit 1)  30 days  4 weeks  
Field Tests  28 days (+6 days)  4 weeks  
     2 weeks Field Test 1 +3 days, 2 weeks Field Test 2 + 3 days  
Follow -up (Visit 2)  1 day (+7 days)   
Washout Period  5 days (+2 days)  1 week  
Follow -up Visit (Visit 3)  1 day (+7 days)   
Interim analysis  of 
nuisance parameter  
(interaction effect)  0 (done in parallel 
during Field Test 1)  0 
Completion of data 
analysis  90 days  12 weeks  
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of Sponsor.                                                                Page 8 of 70  TOTAL Duration  155 days (+22 days)  25 weeks/6 months  
 
 
Adaptive Design: IF significant Interaction Effect  
12 Subject s: Cross-over design  
Enrollment (Visit 1)  30 days  4 weeks  
Field Tests  28 days (+6 days)  4 weeks  
     2 weeks Field Test 1 +3 days, 2 weeks Field Test 2 + 3 days  
Follow -up (Visit 2)  1 day (+7 days)   
Washout Period  5 days (+2 days)  1 week  
Follow -up Visit (Visit 3)  1 day (+7 days)   
Interim analysis  of 
nuisance parameter  
(interaction effect)  0 (done in parallel 
during Field Test 1)  0 
Subtotal  Duration  65 days (+ 22 days)  13 weeks/ 3 months  
 
38 Subject s: Parallel -arm design  
Enrollment (Visit 1)  30 days  4 weeks  
Field Test 1  14 days (+3 days)  2 weeks  
Follow -up (Visit 2)  1 day (+7 days)   
Completion of data 
analysis  90 days  12 weeks  
Subtotal Duration  135 days (+10 days)  18 weeks/4.5 months  
   
Grand TOTAL  
Duration  200 days (+ 32 days)  31 weeks/ 7.5 months  
  
Subject  Duration:  Adaptive Design: IF no Significant Interaction Effect  
28 subject s 
Each subject  receives  both treatments  (cross -over design)  
7 weeks  total study duration on -study per subject  
 
Adaptive Design: IF significant Interaction Effect  
50 subject s: 
• Before the interim analysis, 12 subject s get both treatments 
(cross -over  design ) 
• After the interim analysis, 38 subject s get one treatment (parallel -
arm design ) 
 12 subject s get both treatments = 7 weeks total study duration on -study 
per subject  
38 subjec ts get one treatment = 3 weeks total study duration on -study per 
subject  
 
  
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of Sponsor.                                                                Page 9 of 70  1.2 SCHEMA   
ADAPTIVE DESIGN: NO INTERACTION  EFFECT  (Cross -over Design)  
Prior to  
Enrollment  
-3 months  
 
 
 
 
Fittin g  
Strategy  
 
Visit 1  
Enrollment  
Baseline  
Week 0  
 
 
Field Test 1  
Week 0-2 
(+3 days)  
 
Visit 2  
Week 3  
(+7 days)  
 
 
 
 
Cross Over  
Fitting  
Strategy  
 
Field Test 2  
Week 5-7 
(+3 days)  
 
Visit 3 
Week 8 
(+7days ) 
Exit 
 
 Final Assessments  
- APHAB aided : Field Test 2 hearing aids  
- SSQ-12 aided : Field Test 2  hearing aids  
- QuickSIN unaided, aided (randomized, double -blinded)  
- REM aided (randomized, double blinded)  
- Fitting  Preference Likert scale question  Total N  = 28 :  Obtain informed consent. Screen potential participants  by inclusion and 
exclusion  criteria; obtain history, document.  
- APHAB unaided  
- SSQ-12 unaided  
- Fitting of Hearing Aids for Field Test 1 : Vibe SF or Silk 1X  HCP fit  
- Silk 1X: HCP fit to NAL -NL2 prescriptive target verified by REM  
 
  
HCP fit  
N = 6 + 8 (cross -over design *) Vibe SF  
N = 6 + 8 (cross -over design *) 
* Randomize  
HCP fit 
N = 6 + 8* Vibe SF  
N = 6 + 8* Sound Quality, Speech Understanding & Satisfaction EMA Ratings  
ADEs: Vibe  SF Strategy  
- APHAB aided : Field Test 1 hearing aids  
- SSQ-12 aided : Field Test 1 hearing aids  
- Cross Over Fitting of Hearing Aids for Field Test 2 : Vibe SF or Silk 1X HCP fit  
- Silk 1X: HCP fitted to NAL-NL2 prescriptive target verified by REM  
Sound Quality, Speech Understanding & Satisfaction EMA Ratings  
ADEs: Vibe SF Strategy  5 days 
Washout  
Interim Analysis  after 12 participants, continue  cross -over design                                        
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of Sponsor.                                                                Page 10 of 70  ADAPTIVE DESIGN: INTERACTION  EFFECT DETECTED  (Parallel -arm Design)  
Prior to  
Enrollment  
-3 months  
 
 
 
 
Fitting  
Strategy  
 
Visit 1 
Enrollment  
Baseline  
Week 0  
 
 
Field Test 1  
Week 0 -2 
(+3 days)  
 
Visit 2  
Week 3  
(+7 days)  
 
 
 
 
Cross Over  
Fitting  
Strategy  
 
Field Test  2 
Week 5 -7 
(+3 days)  
 
Visit 3  
Week 8  
(+7days)  
Exit 
 Final Assessments  (completed by 12 participants)  
- APHAB aided : Field Test 2 hearing aids  
- SSQ-12 aided : Field Test 2  hearing aids  
- QuickSIN unaided, aided (randomized, double -blinded)  
- REM aided (randomized, double blinded)  
- Fitting  Preference Likert scale question  Total N  = 50 :  Obtain informed consent. Screen potential participants  by inclusion and exclusion  
criteria; obtain history, document.  
- APHAB unaided  
- SSQ-12 unaided  
- Fitting of Hearing Aids for Field Test 1 : Vibe SF or Silk 1X  HCP fit  
- Silk 1X: HCP fit to NAL -NL2 prescriptive target verified by REM  
 
  
HCP fit  
N = 6 + 19 (parallel -arm design)  Vibe SF  
N = 6 + 19 (parallel -arm design)  Randomize  
HCP fit 
N = 6 Vibe SF  
N = 6 Sound Quality, Speech Understanding & Satisfaction EMA Ratings  
ADEs: Vibe  SF Strategy  
- APHAB aided : Field Test 1 hearing aids  
- SSQ-12 aided : Field Test 1 hearing aids  
- Cross Over Fitting of Hearing Aids for Field Test 2 : Vibe SF or Silk 1X HCP fit  
- Silk 1X: HCP fitted to NAL-NL2 prescriptive target verified by REM  
- FINAL VISIT for parallel arm design: 38 participants  
- QuickSIN  & REM  aided: Field Test 1 hearing aids (only for 38 participants parallel -arm design ) 
Sound Quality, Speech Understanding & Satisfaction EMA Ratings  
ADEs: Vibe SF Strategy  
Interim Analysis after 12 participants ,  additional 38 participants enrolled & complete up to Visit 2 5 days 
Washout  
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of Sponsor.                                                                Page 11 of 70  Schedule of Activities ( SoA) 
 
Procedures  
Screening  
- 3 months  
Enrollment/Baseline  
Visit 1, Week 0  
Field Test 1  
Week 1 -2 +3 days  
Study Visit 2  
Week 3 +7 days  
Washout Period             5 days 
+ 2 days post Visit 2  
 
Field Test 2  
Week 4 -5 + 3 days  
12 subject s completed Visit 3 
 Study Visit 3  
Day 30 + 7 day  
Inclusion/Exlusion Criteria  X        
Demographic (e.g., gender)  X        
Medical history (e.g., Length of hearing loss, 
length of hearing aid use)  X        
Self-perceived hearing loss rating  X        
Hearing Test  X        
Informed consent  X        
Randomization   X       
APHAB unaided   X       
SSQ-12 unaided   X       
Bilateral Hearing Aid fitting:          
Silk 1X Issued, HCP fit  strategy: NAL NL2 REM   (X)  (X)     
Vibe SF  Hearing Aids Issued,   SF strategy   (X)  (X)     
Shipment and Delivery of Field Test 2 Hearing Aids 
at 5 days + 2 days post Visit 2      X    
APHAB aided     X    X 
SSQ-12 aided     X    X 
Sound quality , speech understanding and hearing 
aid satisfication EMA    X   X   
Follow -up Call: EMA data collection  
(+3 days Field Test 1 & 2)    X   X   
QuickSIN, unaided         X 
QuickSIN, aided, hearing aid order randomized, 
double -blinded         X 
QuickSIN, Field Test 1 device  (parallel -arm design)     X*     
REM, hearing aid order randomized, double -
blinded  (cross -over design)         X 
REM , Field Test 1 device (parallel -arm design)     X*     
Fitting Preference Likert question         X 
Adverse device effect (ADE) review and evaluation   X X X  X  X 
Complete electronic Case Report Forms (eCRFs)  X X X X  X  X 
Final Study Visit at Visit 3 for 28 subjects (cross -
over design)         X* 
Final Study Visit at Visit 2 for 38 subject s (parallel -
arm design)     X*     
Final Study Visit at Visit 3 for 12 subjects  
(parallel -arm design)         X* 
Interim Analysis: Interaction Effect Detection  on 
12 subjects        X  
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of Sponsor.                                                                Page 12 of 70  (X): Visit 1: Device Fitting Strategy order randomly issued to subject . Visit 2: Cross Over to other Device Fitting Strategy  
X*: Adaptive  design: detection an alysis of significant interaction effect impacting sample size and study design ( cross -over vs 
parallel -arm design)  
 
2  INTRODUCTION  
 
2.1 STUDY R ATIONALE   
 
Having reliable access to hearing health care services in the United States does not equate  that individuals  
with hearing impairment will purchase and use hearing aids.  Today, an estimated 3.4 million people in the  
US experience hearing study  difficulties, have an objectively measurable hearing loss, but still do not use 
any device to mitigate  their  hearing loss  problem. There are many reasons that an individual  does not 
pursue adopting a hearing healthcare solution. Accessibility and affordab ility are two of the main reasons 
reported in the latest MarkeTrak 10 survey  (Edwards, 2020) . The stigma associated with hearing aids, lack 
of aware ness or lack of confidence that hearing aids would help are other reasons.  
 
Self-fitting (SF)  hearing aids address primarily the accessibility and affordability issues. These SF hearing 
aids may expand the reach of hearing health care by meeting the unmet needs of a segment of people with 
hearing loss who, until now, have rejected  traditional hearing aids.  
 
The Sponsor  is conducting this NSR device study to fulfill one of the  special control s, 21 CFR  § 
874.3325(b)(1) Clinical data must evaluate the effectiveness of the self -fitting strategy …for self -fitting air 
conduction hearing aids . The primary purpose of the SF Study is to validate the effectiveness of the Vibe SF 
strategy based on the device’s intended use and technological characteristics. The SF Study final clinical 
study report  will be part of the 510(k) submission for the Vibe SF hearing aid.  
 
2.2 BACKGROUND   
The Original Hearing Aid Act in 1977 led the FDA to designate hearing aids as medical devices. Hearing Aids 
were listed under the Food and Drug Administration Modernization Act of  1997 (FDAMA ) or the 21st 
Century Cures Act of 2016 as exempt from premarket notification requirements. In October 2018, the FDA 
established the new Class II device type, self-fitting air conduction hearing aid (21 CFR § 874.3325) with 
special controls.   
SF strategy clinical data are described by Sabin et al . (2020)  who conducted a simi lar validation  
investigation on the  predicate device, the self -fitting and direct -to-consumer ( DTC) BOSE® H earing Aid  
(DEN180026, 2018) .  
The Sponsor believes that a 510(k) clearance of this SF device supports  its positioning to fulfil l the 
upcoming FDA proposed rule on  Over -the-Counter (OTC) hearing aids  as required in the 2017 Over -the-
Coun ter (OTC) Heari ng Aid Act.  
2.3 RISK/BENEFIT ASSESSMENT   
 
2.3.1  KNOWN  POTENTIAL RISKS  
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of Sponsor.                                                                Page 13 of 70   
The risk management process for the self -fitting hearing aid system is performed in accordance with the 
requirements stated in ISO 14971:2007, and the risk analysis results are used to identify and implement 
appropriate product development activities.  The risk analysis in the Risk Management File for the self -
fitting hearing aid system conducted by SPONSOR includes the identified risks in 21 C.F.R. § 874.3325 and in 
the validation investigation on the predicate device, the self -fitting and direct -to-consumer (DTC) BOSE® 
Hearing Aid ( see Appendix 1 ). 
Table 1 below lists the identified risks related to the self -fitting system  of the Vibe SF hearing aid and  EasyFit  
web a pplication  (EasyFit ).  
Mitigations to prevent over -amplifications include a safety output limiter which is  a hardware measure for 
limiting the output sound pressure level (OSPL ) in failure mode. Hence, for the implemented cluster, the 
safety limiter is 6 dB above maximum OSPL of  the specific cluster. Other mitigation measures include 
performance testing as electroacoustics and software verification and validation.  Critical use -related 
scenarios (critical tasks) and essential functions have been identified and will be tested and validated in 
Human Factors testing.  
Table 1. Overview of identified risks related to self -fitting  system clinical study  
Identified Risk  Mitigation Measures  Support  
Diminished hearing due to over -
amplification caused by:  
• Excessively high sound output levels 
in the ear canal  
 • Software verification and validation 
(performance testing)  
• Electroacoustic (performance testing)  
• Safety Limiter implemented in design  
• Maximum p ossible output 1 14 dB 
• Screening of subject s to confirm mild -to-
moderate hearing loss   • ANSI S3.22 
electroacoustic 
testing  
Diminished hearing due to over -
amplification caused by:  
• Confusing and switching left and right 
hearing aid  • Safety Limiter implemented in design  
 
Labeling  
• IFU and Workflow show Left/Right Hearing 
Aid (Labeling)  
• L/R mark on the device to distinguish 
between left and right hearing aid  • Software 
verification and 
validation 
(performance 
testing)  
• Design 
verification  
 
Listening fatigue or failure to provide 
sound awareness due to over - or 
under -amplification caused by:  
• Poor fitting  
• Use error  
• Confusion L/R  
 • Software verification and validation 
(performance testing)  
• Electroacoustic (performance testing)  
• Safety Limiter implemented in design  
 
Labeling  
• IFU and Workflow show Left/Right hearing 
aid (Labeling)  
• L/R mark on the device to distinguish 
between left and right hearing aid  • Software 
verification and 
validation 
(performance 
testing)  
• Human factors 
validation  
• Pilot Study   
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of Sponsor.                                                                Page 14 of 70  Identified Risk  Mitigation Measures  Support  
Diminished hearing due to unintended use 
as hearing protection in loud 
environments.  Labeling  
• Do not use this device as hearing 
protection in loud environments.  
• Frequent exposure to loud sounds may 
harm your hearing. Keep the loudness at 
comfortable listening levels. Wear hearing 
protection when exposed to loud 
environmental noise.  • Human factors 
validation  
• Wrongly treated hearing loss  
• Unintended user (severe hearing 
loss) selects the SF hearing aid 
despite having a severe hearing loss.  
Severe hearing loss remains 
untreated and worsens.  • Labeling  
• Web application has built in measures if 
the response is outside the fitting range.  
• Screenin g confirms that subject s have mild -
to-moderate hearing loss  • Human factors 
validati on 
• Software 
verification and 
validation 
(performance 
testing)  
Diminished hearing due to over -
amplification caused by:  
• Hearing ability profiling: Intended user 
does not count how many tones he / 
she hears leading to wrong clusters 
selected.  • Built -in measures in the web application 
to check consistency in the answers of the 
users on how many tones heard.   
• Comfort loudness adjustable by the user 
after the hearing ability profiling.  
Labeling  
• Perform the hearing ability profiling in a 
quiet environment without interruptions 
for the best result.  • Human factors 
validation  
• Software 
verification and 
validation 
(performance 
testing)  
 
 
Acoustic Smartphone App can provide a 
high sound pressure level (SPL) / output 
to the patient's ear  causing discomfort in 
the ear . The tones are extremely short and not 
perceived by most people  
These types of remote controls have been 
marketed for many years and proven to be 
reliable and safe  
Labeling  
• The smartphone generates short tone 
sequences to con trol the hearing aids. Do 
not hold the smartphone close to the ear 
while using the app.  • Human factors 
validation  
 
 
 
2.3.2  KNOWN POTENTIAL BENEFITS  
Hearing aids relieve the strain of hearing, i.e., less strain and more clear hearing. It is anticipated that 
inexperienced wearers will experience improved ease  and better speech understanding  in various  listening 
environments, e.g., watching television, conversations .  
 
Subject s get the chance to try out state -of-the-art modern hearing aids. Inexperienced hearing aid subject s 
gain experience with hearing aids which will help them to make an informed choi ce if they decide to 
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of Sponsor.                                                                Page 15 of 70  purchase hearing aids upon conclusion of the study. Subject s already fitted with hearing aids will gain 
experience with SF hearing aids  as well as the instant -fit completely -in-canal (CIC) form factor . 
 
During screening the hearing of the subject s is checked by HCP thus the subject s gain current information 
about the status of their hearing.  
 
Having to fill out the  EMA surveys  daily may have the benefit that  subject s pay more attention to their 
hearing which might lead to increased perceptiveness of sound  being an  incentive to become more socially 
active. Overall, this  could contribute to their emotional well -being.  
 
2.3.3  ASSESSMENT O F POTENTIAL RISKS AND BENEFITS  
 
Overall, all risk s iden tified  are mitigated as low as possible / below the risk acceptability threshold.  The 
risks associated with the use of the Vibe SF  hearing aid system are acceptable when weighted against the 
expected benefits to the study subject s. The benefit outweighs the ove rall residual risk . 
 
In conclusion, the overall residual risk and the overall risk/benefit profile is acceptable for the clinical study 
using the self -fitting system EasyFit  web app lication  and Vibe SF  hearing aid . 
 
3 OBJECTIVES AND ENDPOINTS  
 
OBJECTIVES  ENDPOINTS  JUSTIFICATION FOR 
ENDPOINTS  
Primary     
Primary Effectiveness    
To demonstrate that the Vibe SF  
strategy is non -inferior to the HCP fit  
strategy in subject ´s perceived 
hearing aid benefit after wearing the 
Vibe SF and Silk 1X HCP fit  hearing 
aids in real -life conditions.  
 
 
        Differences in the benefit scores on 
each of the three communication 
subscales as captured by the 
Abbreviated Profile of Hearing Aid 
Benefit (APHAB) after wearing each 
Vibe SF/ Silk 1X HCP fit  hearing aids 
for 14 days.  
 
The three communication subscales on 
the APHAB are:  ease of communication  
(EC), background noise (BN) and 
reverberant room (RV). There is one 
benefit score (i.e., = unaided - aided) 
for each communication subscale (EC, 
BN and RV) scored after each fitting 
strategy field testing (SF or HCP fit ): 
∆EC(benefit) SF, ∆BN(benefit) SF, 
∆RV(benefit) SF for the Vibe SF hearing 
aids, and  ∆EC(benefit) HCP fit , 
∆BN(benefit) HCP fit , ∆RV(benefit) HCP fit  for 
the Silk 1X HCP fit  hearing aids.  
 Self-reporting questionnaires 
have been commonly used to 
measure subjective hearing 
impairment.  
The APHAB is selected because 
of its known psychometric 
properti es. The APHAB was 
specifically designed to 
quantify auditory disability so 
that the success of the hearing 
aid fitting in reducing disability  
and comparison between 
hearing aid fitting strategies  
may be examined  (Cox & 
Alexander, 1995)  .  
 
The reason to examine each 
subscale independently is to 
investigate  whether the fitting 
strategies provide different 
benefit in varying kinds of 
environments in the real world.  
 
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of Sponsor.                                                                Page 16 of 70  OBJECTIVES  ENDPOINTS  JUSTIFICATION FOR 
ENDPOINTS  
For each subject , the endpoints are 
the 3 communication subscale 
differences between the HCP fit  
subscale (benefit) score and 
corresponding SF subscale (benefit) 
score:  
• ∆EC(benefit) HCP fit  - ∆EC(benefit) SF  
• ∆BN(benefit) HCP fit  - ∆BN(benefit) SF  
• ∆RV(benefit) HCP fit  - ∆RV(benefit) SF 
 
Time point data collected:  
Cross -over Design:  
Visit 1,  2, 3  
 
Parallel -arm Design:  
12 subject s: Visit 1, 2, 3  
38 subject s: Visit 1 and 2   
 
Secondary    
Secondary Hearing Aid Benefit:    
To score  each of the following 
performance measures when the 
subject  is using the Vibe SF and Silk 
1X HCP fit  hearing aid s:   
1. Sound quality , speech 
understanding  and hearing aid 
satisfaction  real-time 
assessment   
 The subject ´s sound quality , speech 
understanding  and hearing aid  
satisfaction Ecological Momentary 
Assessment (EMA)   scores measured 
repeatedly under real-life conditions.  
 
Time point data collected:  
Cross -over Design:  
Field Test 1 and Field Test 2 
 
Parallel -arm Design:  
12 subject s = Field  Test 1 and 2  
38 subject s = Field Test 1  Assessment of perceived 
hearing aid benefit should 
include the dimension 
perceived sound quality , 
speech understanding  and 
hearing aid satisfaction . 
 
Only a couple of studies ha ve 
allowed users to make multiple 
adjustments or sound quality 
judgments under real -life 
conditions . We want to further 
the research on standardizing 
the sound quality and speech 
understanding satisfaction  
assessment  questions asked in 
real-life conditions.  
 
The use of EMA ratings in 
audiology research is growing. 
Apps allow researchers to 
implement the EMA 
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of Sponsor.                                                                Page 17 of 70  OBJECTIVES  ENDPOINTS  JUSTIFICATION FOR 
ENDPOINTS  
methodology using 
smartphones in hearing aid 
outcome research (Wu, Stangl, 
Zhang, & Bentler, 2015) . 
The EMA approach overcome s 
several long -standing problems 
in assessment.  
First, EMA minimizes the 
problem of retrospective 
memory biases in reporting long 
after specific behaviors or 
emotional reactions are emitted 
because respondents can be 
prompted during real -life 
situations  (Schiffman, Stone, & 
Hufford, 2008) . Users may 
remember recent events or very 
emotional events more than 
others . For hearing aid trials , this 
also means users may not 
remember the acoustical 
background of the situation.  
 
Secondly , EMA is 
representative of real life - 
surveys are not filled out in an 
artificial situation during an 
investigational site visit but 
rather  are possible in many 
different situations in the life 
of the subject s. With random 
sampling (random trigger s) it is 
possible to deduct how often 
each situation occurs in 
everyday life, but subject s can 
also trigger a survey in very 
important or difficult 
situations.  
 
Thirdly, EMA is context 
sensitive – subjects may have 
different needs and 
preferences in diffe rent 
situations. This can be 
measured with EMA as the user 
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of Sponsor.                                                                Page 18 of 70  OBJECTIVES  ENDPOINTS  JUSTIFICATION FOR 
ENDPOINTS  
can be asked what situation 
he/she is in right now. Subject s 
can for example pay attention 
to acoustical features, if the 
questionn aire asks for it.  
2. Speech -in-noise recognition 
performance   Speech -in-noise recognition 
performance as measured by the 
Quick Speech -In-Noise test (QuickSIN)  
 
Time point data collected:  
Cross -over Design:  
28 subject s Visit 3  
 
Parallel -arm Design:  
12 subject s Visit 3  
38 subject s Visit 2  This is an objective measure of 
Hearing aid benefit  with  known 
psychometric properties to be 
comparable  to related SF 
strategy research.  
3. Hearing disability in 
communication situations  Hearing disability resulting from 
hearing loss quantified by the short 
form of the Speech, Spatial, and 
Qualities of Hearing Scale for clinical 
use:  the SSQ -12 questionn aire 
 
Time point data collected:  
Cross -over Design:  
Visit 1, 2, 3  
 
Parallel -arm Design:  
12 subject s Visit 1, 2, 3  
38 subject s Visit 1 and 2  This is a subjective measure of 
Hearing aid benefit  with  known 
psychometric properties to be 
comparable  to related SF 
strategy research.  The SSQ -12 
(Noble, Jensen, Naylor, Bhullar, 
& Akeroyd, 2013)  is selected as 
a verified tool  to provide 
insights into other components 
of hearing function.  
Secondary Gain Selection    
Individual frequency -specific real -ear 
gain comparison of the two different 
fittings ( Vibe SF /HCP fit ). Individual frequency -specific real -ear 
gain comparison for the two different 
fitting strategies ( Vibe SF /HCP fit ) for 
each ear as measured with probe -mic 
measures (REM).  
 
Time point data collected:  
Cross -over Design:  
Visit 3  
 
Parallel -arm Design:  
12 subject s Visit 3  
38 subjects Visit 2  Objective comparison of real-
ear gain ( Vibe SF vs. HCP fit ) to 
characterize performance and 
establish the comparability of 
the Vibe SF and HCP fit  
parameters  
Secondary Preference    
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of Sponsor.                                                                Page 19 of 70  Fitting (Vibe SF /HCP fit ) preference 
reported by the subject . Fitting preference between the Vibe 
SF or HCP fit  strategy .  
Subject s will be asked to give their 
response on a 5 -point Likert scale  to 
the following question : Based on your 
listening experiences regarding speech 
under standing, sound quality and 
naturalness for both products, if you 
could keep one p air of these hearing 
aids, which would you choose?  
 
Time point data collected:  
Cross -over Design:  
Visit 3  
 
Parallel -arm Design:  
12 Subject s: Visit 3  Assessment of perceived 
hearing aid benefit should 
include the dimension of fitting 
preference of the subject .  
Secondary Safety Objective    
To estimate the rate of safety when 
the subject  is using the Vibe SF 
hearing aid s. The number of adverse device effects  
(ADEs) in the time period when the 
subject  is using the Vibe SF strategy 
hearing aids.  
 
Time point data collected:  
Cross -over Design:  
Visit 1 -3, Field Tests 1 -2 
 
Parallel -arm Design:  
12 Subject s:  
Visit 1 -3, Field Test 1 -2 
38 Subject s:  
Visit 1 and 2, Field Test 1  Record, track and report 
device -related events as part of 
the risk management  process 
for the SF strategy validation.  
 
4 STUDY DESIGN  
 
4.1 OVERALL  DESIGN  
 
The null hypothesis of the SF Study is that subject ´s perceived hearing aid benefit using  Vibe SF hearing aids 
is inferior to Silk 1X HCP fit  hearing aid s, and the alte rnative  hypothesis  is that subject ´s hearing aids benefit 
using Vibe SF hearing aids is non -inferior to that using Silk 1X HCP fit  hearing aids.  
 
A prospective, randomized  controlled,  adaptive  design , non-inferiority,  pre-market  and NSR device study. 
The first 12 subject s will participate in the cross -over design, after which  an interim analysis of a nuisance 
parameter will be conducted to evaluate whether there is an interaction  effect.  If there is, the design will 
be changed to parallel -arm, the sample size will be increased to 50, and the remaining 38 subject s will 
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of Sponsor.                                                                Page 20 of 70  receive  just one fitting (to which they are randomized).  If there is no significant interaction  effect, the 28 
subject s originally planned will complete the cross -over design.  
 
Cross -over design: 28 subjects  
At the final Visit 3 the order of evaluating hearing aids (Vibe SF  /Silk 1X HCP fit ) will be randomized to 
ensure double -blinding to minimize subject  and HCP bias while conducting the QuickSIN and REM 
laboratory assessments.  
 
Parallel -arm design:  50 subjects  
For 38 subjects,  the final visit will be at Visit 2 and the REM and QuickS in will be tested with the Field Test 1 
device . 12 subjects  will complete the final visit where the  order of evaluating hearing aids (Vibe SF /Silk 1X 
HCP fit) will be randomized to ensure double -blinding to minimize subject and HCP bias while conducting 
the QuickSIN and REM laboratory assessments.  
 
This study has two fitting strategy groups, Vibe SF  and HCP fit .  In subject s who participate in the cross -over 
design, each subject  is in each fitting strategy group for 14 days, 5 -day washout period after cross over and 
total subject  study intervention duration is 7 weeks. In subject s who participate in the parallel -arm design, 
each subject  is in just one fitting strategy for 14 days.  There is no washout period, and no cross -over to the 
other fitting.  
 
A single US University hearing aid research clinic will be the clinical site in this study. The investigational site 
serves 15% Native American, 5% African American  and other diverse American population.  
 
The name of the self -fitting air conduction hearing aid is Vibe SF . The EasyFit  web application is intended to 
support the SF strategy of the Vibe SF.  The Vibe SF strategy is being evaluated in this study.  
To address a possible significant interaction effect, a sample size re -estimation based on the nuisance 
parameter: interaction term will be conducted after 12 subject s have completed Visit 3.  
 
4.2 SCIENTIFIC R ATIONALE FOR STUDY DESIGN  
 
Research of self-fitting  hearing aids is limited , there is only one current published SF validation study  done 
by the predicate device from Bose. Today the landscape of the hearing industry is changing quickly due to 
the rapid advancement of amplification technology as well as changes in federal regulations of the hearing 
aid market.  
 
The sponsor does not kn ow, before initiating the study, whether the interaction between treatment and 
order is significant. It is the company’s belief that an interaction effect is unlikely because many studies in 
the hearing aid literature use cross -over designs, and none menti on a significant interaction effect. 
Therefore, the company prefers not to start with the assumption that it is necessary to conduct a parallel -
arm trial. To address concerns about a possible interaction effect, the sponsor proposes to address this 
potenti al problem by using an adaptive design:  changing to a parallel -arm design  based on a nuisance 
parameter.  The nuisance parameter is the interaction term.   
 
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of Sponsor.                                                                Page 21 of 70  It is important to differentiate between traditional hearing aids and SF hearing devices, not only  in terms of 
device characteristics but also in terms of expected subject  outcomes. Also, it is important to differentiate 
the devices that produce the best patient outcomes across various listening situations. Therefore, there is a 
scientific need to develop an evidence base with well -controlled studies in relation to SF hearing aids.   
 
Assessing the non -inferiority of the SF hearing to HCP fit  hearing was the chosen study design because HCP 
counseling on heari ng loss has been established in research as being best practice.  In the rapidly changing 
distribution of model of hearing healthcare, it may become more likely  a person with perceived hearing loss 
will utilize a self -fitting method as an introduction to h earing care.  In the absence of a best practices model 
involving the HCP, it is necessary to verify that a hearing aid user’s first experience with amplification is 
such that core expected benefits are met with a self -fitting approach.  This does not preve nt future 
intervention with a HCP.  Rather, a self -fitting approach to amplification should provide noticeable benefit 
comparable to that of best practices to overcome key challenges of hearing loss directly related to reduced 
audibility.  In this way, the  new hearing aid wearer can begin experiencing benefits of amplification and 
develop a positive acceptance of hearing healthcare.  
 
It cannot be expected for a SF hearing aid to be superior as the advantages of the SF lie in accessibility and 
ownership not the fitting -process itself. However, in the best interest of the subjects it has to be ensured 
that the hearing aid fitting is not inferior to that what they would get from the standard alternative , i.e., 
being fitted by a HCP.  
 
 
4.3 END OF STUDY DEFINITION  
 
28 subject s are considered to have completed the study when they  have completed all phases of the study 
including the last visit shown in the SoA, Section 1.3 . 
 
In the event an additional 22 subject s are enrolled due to detection of significant interaction effect, these 
are considered to have completed the study when they have completed Visit 2. Refer to SoA, Section 1.3.  
 
The end of th e study is defined as  the last subject ’s (minimum 24th subject , maximum 50th subject ) 
completion of  the last visit shown in the S oA in the study . 
 
5 STUDY POPULATION  
 
5.1 INCLUSION CRITERIA  
 
In order to  be eligible to participate in this study, an individual must meet all of the following criteria:  
• Adults 18 years of age or older,  
• Self-perceived mild to moderate hearing imp airment,  
• Signed informed consent form (ICF),  
• Fluent in English listening and read ing comprehension,  
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of Sponsor.                                                                Page 22 of 70  • With or without prior experience with hearing aids. At least four  subject s and maximum 30%  of the 
total number of subject s enrolled in this study will have prior hearing aid experience.  
• Measured audiogram with at least four of the test frequencies 500 Hz, 1000 Hz, 2000 Hz, 3000 Hz, 
and 4000 Hz within fitting range of Vibe SF  hearing aid  (See Figure  1 below).  
 
Figure 1. The colored area shows the fitting range of Vibe SF Hearing aids with the use of vented click sleeves; the 
hearing loss of the subject s should fall within that area.  
 
5.2 EXCLUSION CRITERIA  
 
An individual who meets any of the following criteria will be excluded from participation in this study:  
 
• Silk 1X ( HCP fit )/ Vibe SF hearing aids do not fit into the person’s ears with any of the offered 
silicon e ‘Click Sleeves’ instant ear tips.  
• Abnormal conditions:  
o Severe hearing loss or deafness in at least one ear.  
o A steep decline in hearing ability within the last 90 days in one or both ears.  
o Active discharge within the last 90 days.  
o Dizziness.  
o A visible deformity of the ear.  
o Pain, or discomfort in the ear, or significant ear wax accumulation.   
o Audiometric air -bone gap equal to or greater than 15 decibels at 500 hertz Hz, 1,000 Hz, 
and 2,000 H z.  
5.3 SCREEN FAILURES  
 
Screen failures are defined as subject s who consent to participate in the study  but are not subsequently 
entered in the study. A minimal set of screen failure information is required to ensure transparent 
reporting of screen failure subject s, to meet the Consolidated Standards of Reporting Trials (CONSORT) 
publishing requirements and to respond to queries from regulatory authorities. Minimal information 
includes demography, screen failure details, eligibility criteria, and any serious adverse event (SAE).  
 

SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of Sponsor.                                                                Page 23 of 70  5.4 STRATEGIES FOR RECRUITMENT AND RETENTION  
 
The study will enroll a  minimum of 28 US subject s and a maximum of 50 US subject s, 18 years  of age  and 
older, inexperienced or experienced (minimum 4, maximum 30%  in total) hearing aid users with perceived 
mild -to-moderate hearing impairment that will be screened to confirm that s/he has bilateral sensorineural 
hearing loss.  
 
Potential subject s will be recruited locally by outreach at the investigator site  (i.e., a single  US University 
hearing aid research clinic) , local advertisements, social media advertisements and professional recruiting 
service . Advertisements will be reviewed and approved by the IRB to assure that they are not unduly 
coercive and does not promise a certainty of cure beyond what is outlined in the consent and the protocol. 
No claims will be made, either explicitly or implicitly, that the device is safe or effective for the purposes 
under investigation, or that the test article is known to be equivalent or superior to any other device. FDA 
considers direct advertising for study subject s to be the start of the informed consent and subject selection  
process.  
 
Study subject s will be reimbursed for travel expenses for each clinic visit not to exceed $50/visit.  
In case a subject  withdraws from the clinical investigation the subject  will receive transport compensation 
covering the number of times he/she has visited the investigation site during the clinical investigation.  
As reimbursement  for their time in filling out the EMA surv eys and wearing the hearing aids  during Field 
Test 1 & 2 , and their testing time during Visit 1, 2, and 3 , a total of US$ 175 will be paid out to 28 subject s as 
outlined below :  
Table 2. 28 Subjects: cross -over design  
SCHEMA  Time  Amount  Payment  
Screening  15 minutes  0  
Visit 1  60 minutes  15  
Field Test 1  14 days  40 55 
Visit 2  60 minutes  15  
Field Test 2  14 days  40 55 
Visit 3  120 minutes  65 65 
TOTAL   US$175 US$175 
 
Table 3. 50 Subjects: parallel -arm design  
12 Subjects  
SCHEMA  Time  Amount  Payment  
Screening  15 minutes  0  
Visit 1  60 minutes  15  
Field Test 1  14 days  40 55 
Visit 2  60 minutes  15  
Field Test 2  14 days  40 55 
Visit 3  120 minutes  65 65 
TOTAL   US$175  US$175  
 
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of Sponsor.                                                                Page 24 of 70  
 
 
 
 
38 Subject s 
SCHEMA  Time  Amount  Payment  
Screening  15 minutes  0  
Visit 1  60 minutes  15  
Field Test 1  14 days  40 55 
Visit 2  60 minutes  15  
TOTAL   US$70 US$70 
 
 
6 STUDY INTERVENTION  
 
6.1 STUDY INTERVENTION (S) ADMINISTRATION  
 
6.1.1  STUDY INTERVENTION  DESCRIPTION  
 
The investigational device Vibe SF hearing aid is a NSR medical device that does not pose a significant risk to 
human subject s based on its intended use. The Vibe SF is intended to amplify sound for individuals 18 years 
of age or older with perceived mild to moderate hearing impairment . It is adjusted by the us er to meet the 
user’s hearing needs through software tools. The device is intended for direct -to-consumer  (DTC)  sale and 
use without the assistance of a hearing care professional  (HCP) . Vibe SF is intended to be sold as a binaural 
set and the Vibe SF strat egy is intended to be binaural. The investigation al device immediate package shall 
bear a label with the following statement: “CAUTION —Investigational device. Limited by Federal (or United 
States) law to investigational use. ” 
The instant fit in-the-ear (ITE) sty le Vibe SF hearing aid uses silicon e ‘Click Sleeves’ which are instant ear tips 
in four different sizes to provide comfort and secure device placement within the ear canal. The click 
sleeves are also used on the global market together w ith the Signia Silk Xperience devices  (e.g., Silk 1X HCP 
fit control device)  and other Signia products.  
All hearing aids  in the study  are provided  in black  housing and marked with ‘R’ and ‘L’,  for right and left side 
respectively,  as displayed in Figure 2 .  
 
 
 a) b) c) 

SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of Sponsor.                                                                Page 25 of 70  Figure 2. Drawings of the Vibe Air  SF hearing aid: a) le ft side housing marked ` L’, b) right side housing marked `R’, c) click sleeve, 
microphone, battery door, removal cord and side/orientation indicator .  
The EasyFit  web application is used to guide the user through the Vibe SF  procedure and to set audiological 
gain parameters and preferred settings on the Vibe SF. EasyFit  web application  is designed to function in 
standard browsers of a user’s compatible smartphone or tablet device. Access to the internet is required 
when using EasyFit web application  during the SF procedure , fine-tuning  and use of volume control . 
Through the Vibe SF hear ing aid, the EasyFit  web app lication  will present several sets of 2 or 3 tones to the 
subject  for hearing ability profiling . Within such a test -tone -set all tones have the same frequency, but they 
differ in intensity level. Depending on the extent of hearing loss, the user will hear all, some or none of the 
presented tones. EasyFit  web application  will ask the user to enter th e number of tones  s/he hear s. A 
selection of screen shots of the fitting process with the EasyFit web application are shown in Figure 3 . 
EasyFit  web application  can activate 4 different “clusters” in the hearing aid. “Clusters” in this context 
means different hearing aid settings. Those settings are the s ame with respect to hearing aid feat ures, e.g., 
noise reduction etc., but they differ in frequency dependent g ain, compression and MPO (maximum power 
output). EasyFit  uses the result of the profiling procedure to select and activate the cluster  and master gain 
setting  that is most suitable for the user. In case of an asymmetrical hearing loss the cluster can diffe r 
across sides. A short additional test ensures the overall gain is comfortable and balanced between the left 
and right ears. After the fitting is completed, the user may further use  EasyFit  to fine -tune the hearing aid 
settings during daily use.  
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of Sponsor.                                                                Page 26 of 70   
Figure 3 Selection of d raft screenshots of hearing ability profiling in the EasyFit web application.  
 
The control hearing aid device , Signia Silk Xperience , has been commercially available in the U.S.  as a Class 
II 510(k) -exempt medical device  since July 2020 in five models: Silk 7X, Silk 5X, Silk 3X, Silk 2X and Silk 1X. 
The performance levels for each model differ in the embedded software configuration but use identical 
hardware. The Silk 1X model will be fitted to the individual hearing thre sholds by a n HCP as per standard 
clinical care. The Connexx Fitting Software will be used to fit NAL -NL2 prescriptive target verified by probe -
mic REM.  The Connexx  programming software allows the HCP access to certain programming parameters 
that are not accessible in the Vibe SF using EasyFit .  Parameters that the HCP can adjust in the Silk 1X  fitting 
are 8 adjustable gain and compression handles, Frequency Compress ion, Feedback cancellation (off, min, 
max).  Silk 1X  does support multiple programs, however only one single program (titled: universal program) 
will be used.  
6.1.2  NONSIGNIFICANT RISK DET ERMIN ATION  

SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of Sponsor.                                                                Page 27 of 70  The Sponsor has determined that both the study and device are n on-significant risk, based on the risk 
profile of this non -invasive device ( see Appendix I), and a review of the Code of Federal Regulations 
definitions and rules regarding significant risk devices.  The following rationale is cited as determination of 
non-significant risk:  
The device does not meet the four elements of the definition for a significant risk device per 21 CFR 
812.3, part (m) in that the device does not pose significant risk to the subject and is not an implant, does 
not support or sustain hum an life, and is not of substantial importance for diagnosis, curing, mitigating, 
preventing impairment to human health or treatment of ESRD patient.  The risk assessment by the 
Sponsor concludes that the device poses minimal risk to the subject.   
 
In Appendix I is a summar y of the test validation studies.  
6.1.3  INVENTORY AND DISPENSING  
Investigator site will store the hearing aids in a locked ro om and cabinet. Only the designated staff at the 
investigator site will conduct the randomization and blinding cod ing and store randomized devices 
according to the sites working procedure. Only the designated staff is able to retrieve and directly give/ship 
out to subject s directly the randomized/blinded hearing aids. HCP may not be a designated staff to conduct 
rando mization, blinding coding, storage, shipment or direct retrieval from storage  of the devices to the 
subject s at Visit 3 .   
 
6.2 PREPARATION/H ANDLING/ STORAGE/ ACCOUNTABILITY  
 
6.2.1  ACQUISITION AND ACCOUNTABILITY  
 
Sponsor  will deliver  the hearing aids  to the  investigat ion site before the first subject  is enrolled in the study.  
 
If for any reason devices need to be returned to the sponsor , investigator site will be provided with 
handling instructions at the study site initiation visit.  
 
Return of  all devices will be picke d-up by the sponsor at the clos e out monitoring visit at the investigat ion 
site.   
 
6.2.2  FORMULATION, APPEARANCE, PACKAGING, AND LABELING  
 
6.2.2.1  INVESTIGATIONAL DEVICE: VIBE SF  
 
Legal Manufacturer of the Vibe SF  hearing aids is WSAUD A/S, Nymoellevej 6, DK -3540 Lynge, Denmark . 
Manufactured for Vibe Hearing, 3033 Campus Dr., Suite W 125, Plymouth, MN 55441  
 
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of Sponsor.                                                                Page 28 of 70  The investigational device will come in a hearing aid case placed in a cardboard box together with a pack of 
batteries, a cleaning brush, cleaning cloth and click sleeves sizes XS, M and L. The hearing aid case will 
contain left and right hearing aid with the click sleeve si ze S attached. See also Figure 3. 
The investigational device will be handed out together with the Safety  and Maintenance Information , a 
Quick start guide and a Quick start card.  
 
Figure 3. Content  enclosed in  the Vibe SF  cardboard box  
The Cardboard  box will bear the following information:  
CAUTION Investigational device. Limited by Federal (or United States) law to investigational use.  
Content: Jewel case with 2 hearing aids, silicon e click sleeves in 4 sizes (XS, S, M & L ), 6 batteries size 10, and 
cleaning tools.  
Warning: For adults 18 years and older with mild to moderate  hearing loss. Contact your primary care 
provider before using this product if you currently experience any of these conditions: (1) Severe hearing 
loss or deafness in at least one ear. (2) A steep decline in hearing ability within the last 90 days in one or 
both ears. (3) Active discharge within the last 90 days. (4) Dizziness. (5) A visible deformity of the ear. (6) 
Pain, or discomfort in the ear, or si gnificant ear wax accumulation.  
 
This NSR device study complies with the abbreviated IDE requirements set forth in (§812.2(b)). Therefore, 
the Vibe SF  is labeled in accordance with §812.5.  
The labeling of our investigational device does not contain any f alse or misleading statements nor imply that 
the device is safe or effective for the purposes being investigated.  
Detailed information on device labeling is in Appendix II.  
 
 

SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of Sponsor.                                                                Page 29 of 70  6.2.2.2  CONTROL DEVICE: SILK 1X  
 
Legal Manufacturer of the Silk 1X hearing aids is Signia GmbH, Henri -Dunant -Strasse 100, 91058 Erlangen, 
Germany  
The control  device will come in a standard hearing aid jewel case enclosed in a cardboard box with the 
following information:  
Brand: Signia  
 
The investigational Site will be provided with Click Sleeves Size X S, S, M and L and Batteries in standard 
packaging to hand out to the participants during standard -of-care fitting  at Visit 1 and Visit 2.  
 
 
6.2.3  PRODU CT STORAGE AND STABILITY  
Devices should be stored in their designated jewel cases or appropriate trays or boxes. Temperature for 
storage should be between 10 to 40 °C (50 to 104 °F). Relative humidity should be 10 to 80% and 
Atmospheric pressure 700 to 1060 hPa.  
 
 
6.2.4  PRE PARATION  
 
Randomization coding and blinding coding need to be done in advance by the des ignated investigational 
site staff. The designated site staff must also set up their inventory so that they are able to track, store, 
deliver and retrieve the properly randomized an d blinded devices designated to the subject  at the time of 
their study visits and when shipping out devices for Field Test 2.  
 
6.3 MEASURES TO MINIMIZE BIAS: RANDOMIZED TREATMENT ORDER  AND BLINDING  

SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of Sponsor.                                                                Page 30 of 70   
To avoid order effect of evaluating  Vibe SF strategy and Silk 1X HCP fit  strategy , a balanced randomization 
list will be generated using approved statistical software . A computer -generated pseudo -random -number 
list will be used for assigning the treatment order.  Assignments will be made either by sealed envelope or 
provided real -time on the sponsor’s electronic database capture (EDC) website on a protected page. New 
hearing -aid users and experienced hearing -aid users will be distributed evenly in the two randomized 
groups.  
 
Cross -Over Design: Minimum 12, Maximum 28 subjects  
At the final visit (Visit 3) , the order of testing the experimental and reference devices will be randomized for 
the QuickSIN  and REM lab tests. Randomization will be handled by a designated person not otherwise 
involved in the study.  
 
During each of the following performance measures, QuickSIN and REM, at Visit 3 when the subject  is using 
the Vibe SF and Silk 1X HCP fit  hearing  aids, the identity of the Vibe SF and Silk 1X will be double blinded to 
the subject  and assessor. An assistant other than the HCP will help secure double blinding during the lab 
assessments by handling  the blinding codes, storing, retrieving and presentin g the appropriate hearing aids  
for evaluation.  
 
During Field Test s 1 and 2 use, blinding is not possible since the option of self -finetuning or finetuning visits 
to the HCP reveals the device under investigation.  
 
6.4 STUDY INTERVENTION  COMPLIANCE  
 
A follow -up call made by  investigation site staff to subject s within the first 3 days of their Field Test 1 and 
Field Test 2 will act as a check that they are wearing their hearing aids and that the EMA data collection  is 
being completed and functioning pr operly.   
 
7 STUDY INTERVENTION  DISCONTINUATION  AND SUBJECT  
DISCONTINUATION /WITHDRAWAL  
 
7.1 DISCONTINUATION  OF STUDY INTERVENTION  
 
In case subject  discontinues study intervention the hearing aids and other study material given are 
returned and the subject is out of the study . Organization of returned  materials/hearing aids  will be 
handled by the Sponsor in collaboration with site. No further follow up is necessary.  
 
7.2 SUBJECT  DISCONTINUATION /WITHDRAWAL  FROM THE STUDY  
 
Subject s are free to withdraw from participation in the study a t any time upon request.  
An investigator may discontinue or withdraw a subject  from  the study for the following reasons : 
 
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of Sponsor.                                                                Page 31 of 70  • If the subject  meets an exclusion criterion (either newly developed or not previously recognized) 
that precludes further study participation  
• Subject  is unable to do Field Test 1 and/or 2 under real -life conditions due to quarantine  or social 
distancing due to COVID -19 p andemic.   
The reason for subject  discontinuation or withdrawal from the study will be recorded on the Study 
completion Case Report Form ( eCRF). Subject s who sign ed the ICF and are randomized but do not receive 
the study intervention may be replaced.  Subject s who sign ed the ICF, and are randomized and receive the 
study intervention , and subsequently withdraw, or are withdrawn or discontinued from the  study, will be 
replaced  if the minimum number of 24 subject s has yet to be enrolled.  
 All data is collected during use of the investigational device. In case a patient is withdrawn from the study 
there is no further data collection needed, except in the case the patient would r eport an adverse event 
which would be seen as at least possible related to the treatment with the device. In this case the patient 
will be followed up until the event is resol ved.  
Data collected before withdrawal of consent will be kept in the study.  
 
7.3 LOST TO FOLLOW -UP 
 
A subject  will be considered lost to follow -up if he or she fails to return for scheduled visits and is unable to 
be contacted by the study site staff.  
The following actions must be taken if a subject  fails to return to the clinic for a required study visit:  
• The site will attempt to contact the subject  and reschedule the missed visit and counsel the subject  
on the importance of maintaining the assigned visit schedule and ascertain if the subject  wishes to 
and/or should continue in the stu dy. 
• Before a subject  is deemed lost to follow -up, the investigator or designee will make every effort to 
regain contact with the subject  (where possible, 3 telephone calls and, if necessary, a certified 
letter to the subject ’s last known mailing address or  local equivalent methods). These contact 
attempts should be documented in the subject ’s medical record or study file.  
 
Should the subject  continue to be unreachable, he or she will be considered to have withdrawn from the 
study with a primary reason of lost to follow -up. 
 
8 STUDY ASSESSMENTS AND PROCEDURES  
 
8.1 EFFECTIVENESS  ASSESSMENTS  
Data are collected via questionn aires, laboratory speech testing and EMA surveys during field use. An 
overview is given below in  Table 4 . 
Stage  Intervention  Method  
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of Sponsor.                                                                Page 32 of 70  Screening  Otoscopy  
Tympanometry  
Audiometry  Otoscope, tympanometer  and standard audiometer performed 
by HCP.  
Hearing in Noise Question  HCP asks subject : Do you have trouble hearing in noise? Y/N  
Self-Perceived Hearing Loss 
questionn aire HCP asks subject  to describe their hearing loss on a 4 -point 
scale:  
1. No Trouble  
2. A little trouble  
3. A lot of trouble  
4. Cannot hear  
Visit 1  Questionn aires for primary 
and secondary endpoints 
on effectiveness  
 • APHAB  
The APHAB inventory yields scores for speech communication 
in quiet, reverberant, and noisy environments, and also 
measures aversiveness of loud sounds.  
 
• SSQ-12  
The SSQ -12 includes the factors speech hearing, spatial 
hearing, qualities of hearing, and listening effort.  
 
➔ Both completed for unaided condition (irrespective of 
hearing aid experience)   
Randomized Vibe  SF or Silk 
1X HCP fit  hearing aids : 
Bilateral Hearing Aid fitting  EasyFit  web application (Vibe  SF strategy) performed by 
subject .  Connexx  Fitting Software NAL -NL2, verified with 
probe -mic REM ( Silk 1X HCP fit  strategy ) performed by HCP . 
Fine -tuning  For Vibe SF strategy , with fine -tuning dialog on EasyFit  web 
application  done independently by subject .  For Silk 1X HCP fit , 
fine-tuning with HCP as is standard clinical practice.  
Field Test 1  Fine-tuning  
Situation tuning  For Vibe SF strategy , with fine -tuning dialog and situation 
tuning  is performed with the  EasyFit  web app lication   by the 
subject .  For Silk 1X HCP fit  strategy,  fine-tuning appointment 
with HCP if necessary due to persistent need for fine -tuning 
that cannot be resolved with the situation tuning using the 
Signia App.  
Follow -up to ensure EMA 
survey data capture  Phone call from investigational staff approximately 3+3 days 
after visit to ensure that  daily  EMA surveys  are being 
completed; any questions related to data collection may be 
answered. Questions regarding the hearing aids may  NOT  be 
answered  and subject  will be reminded t o refer to the study 
information provided to them at Visit 1.  
Sound quality ,  speech 
understanding  and hearing 
aid satisfaction ratings for 
secondary endpoint on 
effectiveness  Subject s will be asked via their  study  smartphones to give short 
ratings of sound quality  and speech understanding satisfaction 
in their current listening situation. This EMA is a methodology 
involving repeated surveys to collect data describing subject s’ 
current or very recent experiences in their real -life conditions .  
Visit 2 (only 
cross -over 
design)  Questionn aires for primary 
and secondary endpoint on 
effectiveness  • APHAB  
• SSQ-12 
➔ Both completed Aided (Field Test 1 device)  and if 
necessary, assistance given by HCP  
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of Sponsor.                                                                Page 33 of 70  Field Test 1  Vibe SF Strategy 
or Silk 1X HCP fit  hearing 
aids put in storage  Each subject ´s Vibe SF or Silk 1X HCP fit  hearing aids of the 
Field Test 1 will be  blind coded and  stored so that the speech 
test at the final visit  (Visit 3)  may be done with the exact 
settings used during the Field Test 1 (i.e., including fine -
tuning).  
Cross Over Vibe SF or Silk 
1X HCP fit  hearing aids : 
Bilateral Hearing Aid fitting  EasyFit  web application (Vibe SF strategy) performed by 
subject .  Connexx  Fitting Software NAL -NL2, verified with 
probe -mic REM (Silk 1X HCP fit  strategy) performed by HCP . 
(only cross -over design)  
Fine -tuning  For Vibe SF strategy , with fine -tuning dialog on EasyFit  web 
application  done independently by subject .  For Silk 1X HCP fit , 
fine-tuning with HCP as is standard clinical practice.  
(only cross -over design)  
Visit 2 (only 
parallel -arm 
design)  Questionnaires for primary 
and secondary endpoint on 
effectiveness  • APHAB  
• SSQ-12 
➔ Both completed Aided (Field Test 1 device) and if 
necessary, assistance given by HCP  
Speech Test for secondary 
endpoint on effectiveness  
 • QuickSIN  
➔ Unaided  
➔ Aided ( Field Test 1 device ) 
 
A speech test is included to give objective data on speech 
understanding with the Field Test 1  hearing aids.  
Fitting verification of “final 
fit” 
 REM of Field Test 1 device  for gain comparison  
Washout 
Period  
(only cross -
over design)  5 day  + 2-day period of not 
wearing any study devices  Upon completing Visit 2, the site will collect the hearing aids 
fitted at Visit 2, store them and send them out upon 
completing the 5 -day washout period.  
Field Test 2  
(only  cross -
over design)  See Field Test 1  See Field Test 1  
Visit 3  
(only cross -
over de sign) Questionn aires for primary 
and secondary endpoint on 
effectiveness  • APHAB  
• SSQ12  
➔ Both completed Aided (Field Test 2 device) and if 
necessary, assistance given by HCP  
Speech Test for secondary 
endpoint on effectiveness  
 • QuickSIN  
➔ Unaided  
➔ Aided (device order randomized and double -blinded)  
 
A speech test is included to give objective data on speech 
understanding with the Vibe SF and Silk 1X HCP fit  hearing 
aids.  
 
Reasons to do speech testing for all three conditions at the 
end of the study:  
1. Otherwise, not able to do perform double -blinded.  
2. The cross -over design minimizes  ordering bias effects.  
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of Sponsor.                                                                Page 34 of 70  Fitting verification of “final 
fit” 
 REM of both fitting strategies ( Vibe SF /HCP fit ) for gain 
comparison, device order randomized and double -blinded.  
 
Fitting Preference  Subject s will be asked  to respond to  the following question on 
a 5-point Likert scale: Based on your listening experienc es 
regarding speech understanding, sound quality and 
naturalness for both products, if you could keep one p air of 
these hearing aids, which would you choose?  
Table 4. Overview of test tools utilized  
 
8.1.1  SCREENING  
Potential subject s will be recruited locally by outreach at the investigator sites, local advertisements, social 
media advertisements and professional recruiting service. Initial phone/electronic screening will include the 
question of whether he/she has trouble hearing in noise. If no, they w ill be excluded. Those remaining will 
then be asked to rate on a scale of 1 -4 her/his perceived hearing loss (no trouble, a little trouble, a lot of 
trouble, and cannot hear). Listeners at the two extremes will be excluded.  
Listeners with appropriate respo nses are provided an overview of the study intent ( subject  information) 
and invited into the clinic to be assessed for eligibility, according to inclusion and exclusion criteria, as 
described in Section  5.1 and 5.2 . 
The session begins with otoscopy, tympan ometry and a standard audiometric evaluation consisting of air 
and bone conduction thresholds for each ear. If it is determined they have mild -to-moderate hearing 
impairment and fulfil all inclusion criteria  they will be given study subject  information and asked for their 
voluntary informed consent to participate in the clinical study.  
If at this time a subject is identified with significant asymmetries  in hearing, the HCP will refer them to an 
audiologist  and/or ENT for follow -up and subject will be excluded from the study (screen failure).  
 
 
8.1.2  VISIT 1  
Subject s complete two questionn aires concerning unaided hearing1: the APHAB and SSQ -12. The subject s 
can ask questions, and the HCP or assistant reads through  the filled -out questionn aires with the subject  to 
make sure everything is understood and filled out appropriately.  
 
 
1 Participants that have experience with hearing aids are nonetheless asked to fill out the questionnaires as they would without  the 
use of their hearing aids in order to have the same baseline for all participants.  
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of Sponsor.                                                                Page 35 of 70  Investigational staff complete the randomization process to determine which p air of study hearing aids the 
subject  will receive.  
Hearing aid fitting is conducted in a quiet dedicated hearing aid fitting and counselling room.  
The subject s starting with the Vibe SF  strategy , independently fit their Vibe SF hearing aids bilaterally 
themselves using the EasyFit  web app lication  on the study smartphone  provided to them . They are 
provided with Vibe SF Safety and Maintenance Information , Quick-Start Guide and a Quick-Start Card. The 
HCP will not interfere or assist subject  in fitting their hearing aids .  
For the subject s starting with the HCP fit  strategy , an HCP fit s the Silk 1X  hearing aids bilatera lly using the 
Connexx  fitting software to NAL-NL2 validated prescription target , probe -mic REM  and conduct fine -tuning 
as is standard clinical practice.  
All subject s are given a user manual  for the hearing aids , along with instructions by the HCP or research 
assistant on how to use the EMA app  and study smartphone . Subject s starting with the Silk 1X  (HCP fit  
strategy ) will be provided counselling on the use of the  Silk 1X  hearing aids and  Signia  App ( remote -control 
smartphone  app for situation tuning ). 
The EasyFit  web application guides the user through the SF procedure as well as the fine -tuning and volume 
control functionality. Subject s who start using the Silk 1X HCP fit  strategy hearing aids  will receive 
instructional material on how to use the Signia App for situation tuning  as per standard of care . 
Subject s in both groups are instructed to listen to as many listening environments as possible and enter 
their sound quality , speech understanding  and hearing aid  satisfaction ratings  when randomly prompted by 
the clinical study smartphone, and subject s may at any time self -enter a rating. The investigational staff will 
practice with the subject s until they ha ve observed that the subject  is able to successfully enter their sound 
quality , speech understanding  and hearing aid  satisfaction EMA ratings without any assistance from the 
investigational staff.  
Subject s are asked to report any ADEs  occurring during fie ld use.  
8.1.3  FIELD TEST 1  
All subject s wear their first p air of study hearing aids for two weeks. Since the investigation is designed as a 
cross -over design in order to be able to do within -subject  comparisons, a two -week period was chosen to 
allow for acclimatization and fine -tuning but not prolong the field test to an extent where it is likely that 
subject s would drop out of the study or be less motivated in the second field test.  
The EMA rating  question s on subject ´s sound quality , speech understanding  and hearing aid  satis faction is 
filled out in various listening condition s daily . The EMA consists of a short survey that is triggered randomly 
four times during the entire day and may also be ente red at any time the subject  wants to enter a rating.  
The EMA survey comprises of four single/multiple choice questions (or three, if the situation does not 
involve speech) which are:  
1. Current situation,  
2. Sound quality,  
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of Sponsor.                                                                Page 36 of 70  3. Speech understanding,  
4. Satisfaction  
If the timing is inconvenient (e.g., driving a car), the subject  can delay the response to the survey ( reminder 
is given to not delay the response unduly, e.g., for more than 1 hour ). 
Phone calls (approximately after 3 days +3 days field testing) are scheduled with  investigational staff. These 
calls are intended to ensure that all EMA data collection tools are functioning and subject s are reminded to 
report any adverse device effects  (ADE) occurring during field use. The subject  also has the possibilit y to 
call/e -mail the investigation staff when needed; however, to mitigate the potential for introducing bias 
through counselling of the self -fit group, any questions about the Vibe SF fitting strategy  or how to use the 
device will not be answer ed by the investigational staff.   
For the subject s who start in the HCP fit  strategy  group, b ased on complaints the subject s have about 
sound quality, the audiologist/HCP is able to invite the subject  for an in -person fine -tuning visit and adjust 
the fitting on their Silk 1X  as in a real -life HCP fit ting (standard clin ical care).  
Subject s are asked to report any ADEs occurring during field use.  
All communication with the HCP and/or investigation staff during the field tests will be documented and 
saved.  
8.1.4  VISIT 2  
Subject s return to the clinic after approximately two weeks Field Test 1 use.  Subject s complete two 
questionn aires: the APHAB and the SSQ -12, to reflect their hearing experience  aided with the Field Test 1 
hearing aids . An HCP or assistant reads through the filled -out questionn aires with the subject  to make sure 
everything is understood and filled out sufficiently.  
Subject s are asked to report any ADEs  occurring during field use.  
Cross -over design:  
The Field Test 1 HCP fit  strategy  subject s now c ross over to the Vibe SF strategy group . Subject s 
independently fit their Vibe SF hearing aids bilaterally themselves using the EasyFit  web app lication  on the 
study  smartphone. They are provided with the Vibe SF  Safety and Maintenance Information,  Quick -Start 
Guide and Quick -Start Card  (see Appendix II) . The HCP will not interfere or assist the subject  with the self -
fitting.  
The Field Test 1 Vibe SF strategy  subject s now cross over to HCP fit  strategy group . An HCP fit s the Silk 1X 
hearing aids bilaterally using the Connexx  fitting software, to NAL -NL2 validated prescription target , probe -
mic REM  and conducts fine -tuning as is standard clinical practice.  
The hearing aids of the Field Test 1 are stored without altering the set tings to be used in the REM  and 
speech  tests of the final visit  (Visit 3) .  
Parallel -arm design :  
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of Sponsor.                                                                Page 37 of 70  12 subjects : The Field Test 1 Vibe SF strategy subjects now cross over to HCP fit strategy group. An HCP fits 
the Silk 1X hearing aids bilaterally using the Connexx fitting software, to NAL -NL2 validated prescription 
target, probe -mic REM and conducts fine -tuning as is  standard clinical practice.  
The hearing aids of the Field Test 1 are stored without altering the settings to be used in the REM and 
speech tests of the final visit (Visit 3).  
38 subjects : This is their final visit. The subjects will not cross over to the other fitting strategy . 
Effectiveness is measured with QuickSIN in an unaided condition and aided with Field Test 1  fit hearing aids  
in a sound attenuated booth. REM will be conducted on Field Test 1 hearing aids.  
8.1.5  WASHOUT PERIOD  (ONLY FOR CROSS -OVER DESIG N) 
Upon completing Visit 2, the site will collect the hearing aids fitted at Visit 2, store them and send them out 
to subjects upon completing the 5 -day washout period.  
8.1.6  FIELD TEST 2  (ONLY FOR CROSS -OVER DESIGN)  
Field Test 2 will be conducted the same as stated in 8.1.3 . Field Test 1 . 
8.1.7  VISIT 3  (ONLY FOR CROSS -OVER DESIGN)  
At the final session after approximately 4 weeks of total field use  with a 5-day washout period after two 
weeks  of field use , each subject  return s the hearing aids from  their second field use test . 
Subject s are asked to report any ADEs  occurring during field use.  
Subject s again complete two questionn aires: the APHAB and the SSQ -12, reflecting their hearing 
experience  aided with the Field Test 2 hearing aids . An HCP or assistant reads through the filled -out 
questionn aires with the subject  to make sure everything is understood and filled out sufficiently.  
Effectiveness is measured with QuickSIN  in an unaided condition and aided with the Vibe SF and Silk 1X HCP 
fit hearing aids  in a sound attenuated booth. Aided testing will be conducted double -blinded and subject  is 
given their field test 1 and 2 devices ( Vibe SF and Silk 1X HCP fit  hearing aids ) in randomized order.  
REM will be conducted double -blinded, and the subject  is given field test 1 and 2 devices ( Vibe SF & Silk 1X 
HCP fit  hearing aids ) in randomized order.  
The subject  will be asked to fill out a 5 -point Likert scale to respon d to the prompt : Based on your listening 
experiences regarding speech understanding, sound quality and naturalness for both products, if you could 
keep one p air of these hearing aids, which p air would you choose : Greatly pr efer A, Somewhat Prefer A, No 
Preference, Somewhat Prefer B, Greatly Prefer B.  
 
8.2 SAFETY AND OTHER ASSESSMENTS  
 
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of Sponsor.                                                                Page 38 of 70  Stage  Intervention  Method  
For the 
duration of the 
study  Secondary endpoint on 
device safety  Subject s are asked repeatedly to report any adverse device 
effect s they experience:  
• Instruction during first Visit (Visit 1).  
• At follow -up phone call during first field test.  
• At Second Visit (Visit 2).  
• At follow -up phone call during second field test.  
• At final v isit (Visit 3).  
 
8.3 ADVERSE EVENTS AND S ERIOUS ADVERSE EVENTS  
 
8.3.1  DEFINITION OF ADVERSE EVENTS (AE)  
Adverse event , as defined according to ISO1455, means any untoward medical occurrence , unintended 
disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subject s, users or 
other persons, whether or not related to the investigational medical device and whether anticipated or 
unanticipated.  
 
Note 1: This d efinition includes events related to the investigational device or comparator.  
Note 2: This definition includes events related to the procedures involved.  
Note 3: For users or other persons, this definition is restricted to events related to the use of inv estigational medical 
devices or comparators.  
 
An Adverse event related to the use of an investigational medical device is called an Adverse Device Effect.  
This definition includes adverse events resulting from insufficient or inadequate instructions for us e, 
deployment, implantation, installation, or operation, or any malfunction of the investigational medical 
device. This definition includes any event resulting from use error or from intentional misuse of the 
investigational medical device. It also include s comparator if comparator is a medical device.  
 
8.3.2  DEFINITION OF SERIOUS ADVERSE EVENTS (SAE)  
A Serious Adverse event is an adverse  event that led to any of the following : 
a) death,   
b) serious deterioration in the health of the subject, users, or other persons as defined by one or more of 
the following:   
1) a life -threatening illness or injury, or  
2) a permanent imp airment of a body structure or body function  including chronic disease, or  
3) in -patient or prolonged hospitalization, or  
4) medical  or surgical intervention to prevent life -threatening illness or injury or permanent 
impairment to a body structure or a body function,  
c) fetal distress, fetal death or a congenital abnormality or birth defect  including physical or mental 
impairment  
Note : Planned hospitalization for a pre -existing condition, or a procedure required by the study, without serious 
deterioration in health, is not considered a SAE.  
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of Sponsor.                                                                Page 39 of 70   
Unanticipated serious adverse device effect (USADE) is a serious adverse device effect which by  its nature, 
incidence, severity or outcome has not been identified in the current risk assessment .  
Note: Anticipated serious adverse device effect (ASADE) is an effect which by its nature, incidence, severity or outcome 
has been identified in the risk assessment .  
 
8.3.3  CLASSIFICATION OF AN ADVERSE E VENT  
8.3.3.1  SEVERITY OF EVENT  
For adverse events ( AEs) the following guidelines will be used to describe severity.  
 
• Mild – Events require minimal or no treatment and do not interfere with the subject ’s daily 
activities.   
• Moderate – Events result in a low level of inconvenience or concern with the therapeutic 
measures. Moderate events may cause some interference with function ing. 
• Severe – Events interrupt a subject ’s usual daily activity and may require systemic drug therapy or 
other treatment. Severe events are usually potentially life -threatening or incapacitating.  Of note, 
the term  “severe” does not necessarily equate to “ serious”.]  
 
8.3.3.2  RELATIONSHIP TO STUDY INTERVENTION  
All adverse events ( AEs) must have their relationship to study intervention assessed by the clinician who 
examines and evaluates the subject  based on temporal relationship and his/her clinical judgment. The 
degree of certainty about causality will be graded using the categories below. In a clinical trial, the study 
product must always be suspect.  
 
• Related  – The AE is known to occur with the s tudy intervention , there is a reasonable possibility 
that the study intervention caused the AE, or there is a temporal relationship between the study 
intervention and event. Reasonable possibility means that there is evidence to suggest a causal 
relationsh ip between the study intervention and the AE.  
• Not Related  – There is not a reasonable possibility that the administration of the study intervention 
caused the event, there is no temporal relationship between the study intervention and event 
onset, or an al ternate etiology has been established.  
 
8.3.3.3  EXPECTEDNESS  
The Sponsor and the independent Medical Monitor will be responsible for determining whether an adverse 
event (AE) is expected or unexpected.  An AE will be considered unexpected if the nature, severity, or 
frequency of the event is not consistent with the risk information previously desc ribed for the study 
intervention . 
8.3.4  TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW -UP 
The occurrence of an adverse event (AE) or serious adverse event ( SAE) may come to the attention of study 
personnel during study visits and interviews of a study subject  presenting for medical care, or upon review 
by a study monitor.  
 
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of Sponsor.                                                                Page 40 of 70  All AEs, including local and systemic reactions not meeting the criteria for SAEs, will  be captured on the 
appropriate case report form (CRF). Information to be collected includes event description, time of onset, 
clinician’s assessment of severity, relationship to study product (assessed only by those with the training 
and authority to make  a diagnosis), and time of resolution/stabilization of the event. All AEs occurring while 
on study must be documented appropriately regardless of relationship. All AEs will be followed to adequate 
resolution.  
 
Any medical condition that is present at the time that the subject  is screened will be considered as baseline 
and not reported as an AE. However, if the study subject ’s condition deteriorates at any time during the 
study, it will be recorded as an AE.  
 
Further details can be found in the Study Safety Plan.  
 
8.3.5  ADVERSE EVENT REPORTING  
The investigator must record non -serious adverse events and report them to the Sponsor in a timely 
manner  after the investigator first learns of the adverse event.  AEs which are non -serious not related to 
the research procedures does not have to be reported to the IRB  but will be reviewed by the Sponsor and 
the Independent Medical Monitor .  
In case however t hat the event is unexpected AND  more likely than not related to the research procedures 
it shall be reported to the IRB within 5 days of Investigator receiving notice of the event , as per IRB local 
guidelines .  
 
8.3.6  SERIOUS ADVERSE EVENT REPORTING  
The study i nvestigator shall report an Unanticipated Adverse Device Effect to the study sponsor and to the 
reviewing Institutional Review Board (IRB) as soon as possible, but in no event later than 5 working days  (as 
per IRB local guidelines)  after the investigator first learns of the effect.  The study sponsor is responsible for 
conducting an evaluation of an unanticipated adverse device effect and shall report the results of such 
evaluation to the Food and Drug Administration (FDA)  within 10 working days after the sponsor first 
receives notice of the effect. Thereafter, the sponsor shall submit such additional reports concerning the 
effect as FDA requests.  
 
The sponsor must immediately conduct an evaluation of an y unanticipated adverse device effect.  
If the sponsor determines that an unanticipated adverse device effect presents an unreasonable risk to 
subjects, the sponsor must terminate all investigations or parts of the investigations presenting that risk as 
soon as possible. Termination must occur no later than 5 working days after the sponsor makes this 
determination and no later than 15 working days after the sponsor first received notice of the effect.  
Resumption of Terminated Studies:  
For a nonsignificant r isk device investigation, a sponsor may not resume a terminated investigation without 
IRB approval. If the nonsignificant risk study was terminated for unanticipated adverse device effects, the 
sponsor must also obtain FDA approval.  
 
 
8.4 UNANTICIPATED PROBLEMS  
 
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of Sponsor.                                                                Page 41 of 70  8.4.1  DEFINITION OF U NANTICIPATED PROBLEMS (UP)  
 
Unanticipated problems are defined as problems involving risks to subject s or others to include, in general, 
any incident, experience, or outcome that meets all of the following criteria:  
• Unexpected in terms of nature, severity, or frequency given (a) the research procedures that are 
described in the clinical investigation plan -related documents, such as the approved research Clinical 
Investigation Plan and informed consent document; and (b) the characteristics of the subject  
population being studied;  
• Related or possibly related to participation in the research (“possibly relate d” means there is a 
reasonable possibility that the incident, experience, or outcome may have been caused by the 
procedures involved in the research); and  
• Suggests that the research places subject s or others at a greater risk of harm (including physical, 
psychological, economic, or social harm) than was previously known or recognized.  
 
This definition could include an unanticipated adverse device effect, any serious adverse effect (USADE) on 
health or safety or any life -threatening problem or death caused b y, or associated with, a device, if that 
effect, problem, or death was not previously identified in nature, severity, or degree of incidence in the 
investigational plan or application (including a supplementary plan or application), or any other unanticipa ted 
serious problem associated with a device that relates to the rights, safety, or welfare of subjects  (21 CFR 
812.3(s)).   
 
8.4.2   UNANTICIPATED PROBLEM REPORTING  
An investigator shall submit to the sponsor and to the reviewing Institutional Review Board (IRB)  a report of 
any unanticipated adverse device effect occurring during an investigation as soon as possible, but in no 
event la ter than 10 working days after the investigator first learns of the effect (21 CFR 812.150(a)(1)), A 
sponsor who conducts an evaluation of an unanticipated adverse device effect under 812.46(b) shall report 
the results of such evaluation to the Food and Dr ug Administration (FDA) and to all reviewing IRB's and 
participating investigators within 10 working days after the sponsor f irst receives notice of the effect. 
Thereafter the sponsor shall submit such additional reports concerning the effect as FDA reques ts (21 CFR 
812.150(b)(1)).    
 
8.4.3  REPORTING UNANTICIPATED PROBLEMS TO SUBJECT S  
In case an unanticipated problem would concern o ther study subject s they will be contacted by the study 
investigator.  
 
9 STATISTICAL CONSIDERATIONS  
 
9.1 STATISTICAL HYPOTHE SES  
 
9.1.1  PRIMARY  
 
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of Sponsor.                                                                Page 42 of 70  The primary purpose of the SF Study is to validate the effectiveness of the Vibe Air  SF strategy based on the 
intended use and technological characteristics.  
 
Please refer to Section 3 for more detail about the hypotheses.  There are 3 APHAB communication 
subscales that contribute to the perceived benefit (response condition), and each su bscale benefit (EC, BN, 
RV) must simultaneously demonstrate the non -inferiority of Vibe SF  strategy to HCP fit  strategy.  Note that 
higher means are worse.  
 
• Ho EC(benefit):  ∆EC(benefit) HCP fit  - ∆EC(benefit) SF > 26     vs      
Ha EC(benefit):  ∆EC(benefit) HCP fit  - ∆EC(benefit) SF < 26  
• Ho BN(benefit): ∆BN(benefit) HCP fit  - ∆BN(benefit) SF > 27     vs      
Ha BN(benefit): ∆BN(benefit) HCP fit  - ∆BN(benefit) SF < 27  
• Ho RV(benefit): ∆RV(benefit) HCP fit  - ∆RV(benefit) SF > 28     vs      
Ha RV(benefit): ∆RV(benefit) HCP fit  - ∆RV(benefit) SF < 28  
These are non -inferiority tests comparing the subject ´s perceived hearing aid benefit as measured by the 
difference in each of the three APHAB communication benefit subscales when th e hearing aid is HCP fit  
compared to when it is Vibe SF  by the subject .  The non -inferiority margin (NIM)  depends on the 
communication benefit subscale, according to Cox  (1995) , and these are the minimum clinically important 
differences on each of t he three communication benefit subscales.  
 
9.1.2  SECONDARY  
The secondary objectives do not include any hypothesis tests.  However, they will not be analyzed unless 
the primary effectiveness hypothesis test passes (i.e., rejects all 3 null hypotheses).   
Descriptive statistics will be reported on each endpoint by f itting strategy and overall, according to the list 
in Section 9.4.1.1. In addition, some endpoints require more detailed description.  Additional descriptive 
statistics that will be reported are listed with the endpoints.  
EMA Scores: Descriptive statistics  of the scores will be reported by fitting strategy and measurement time 
for each real -life condition.  
 
QuickSIN Scores: Descriptive statistics of the scores will be reported by fitting strategy and measurement 
time.  
 
SSQ-12 Scores: Descriptive statistics of the scores will be reported by fitting strategy and measurement time 
for each subscale.  
 
Gain Selection: Descriptive statistics of the probe -mic REM will be reported by fitting strategy and 
measurement time.  
 
Fitting Preference: Descriptive statistics of the scores will be reported by fitting strategy and measurement 
time.  
 
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of Sponsor.                                                                Page 43 of 70  Safety Analyses: It is very unlikely that any device -related adverse events will be reported during this NSR 
device study. However, those that are reported will be tabulated by seve rity (mild -moderate -severe), 
seriousness (serious or non -serious) and relatedness (related, not related).  
 
9.2 SAMPLE SIZE  DETERMINATION  
 
The sample size was estimated for the Primary Effectiveness Objective; that is the only objective with a 
hypothesis test. The sample size of 24 was estimated using Pass 2019 and the following parameters:  
Parameter  Value  
Difference between HCP fit  and Vibe SF  
scores ( δ) 
• EC(benefit)  
• BN(benefit)  
• RV(benefit)   
• δ = ∆EC(benefit) HCP fit it - ∆EC(benefit) SF = 0 
• δ = ∆BN(benefit) HCP fit it - ∆BN(benefit) SF = 0 
• δ = ∆RV(benefit) HCP fit it - ∆RV(benefit) SF = 0 
SD (σ) of scores within a fitting strategy 
and for the difference between Vibe SF  
and HCP fit , assuming independence 
(√(2σ2))*  
• EC(benefit)  
• BN(benefit)  
• RV(benefit)   
 
 
• σ = 24.3;     σ DIFF = 34.4  
• σ = 25.6;     σ DIFF = 36.1  
• σ = 25.5;     σ DIFF = 36.2  
(Leohler & et al, 2017)  
Non -inferiority margins (NIMs)  
• EC(benefit)  
• BN(benefit)  
• RV(benefit)  
  
• EC(benefit) = 26  
• BN(benefit) = 27  
• RV(benefit) = 28  
(Cox & Alexander, 1995)  
Power  90% on all 3 tests simultaneously, or 96.5% on each 
individually (.9653 = .90)  
Alpha   5% on all 3 tests simultaneously  
Test Type  Paired t -Tests for Non -Infer iority  
 
* The variance of the difference of two means is used, not 4 means, even though this is the difference of differences.  The rea son 
is that the baseline value (unaided) from which benefit is measured is the same for the SF period and the HCP fit  period.  
Ther efore, the difference of differences reduces to the difference between the aided SF score and aided HCP fit  score.  
  
**     All 3 tests must simultaneously have p<.05  
The sample sizes were estimated for each test at 80% and 90% power, as shown in the table below.  The 
NIMs were chosen because each listening condition will be analyzed independently in order to determine if 
there are significant differences in each  specif ic listening conditions.  The largest sample size required for 
combined 90% power was 23.  We will increase this to 24 so that the cross -over periods are balanced.  A 
sufficient number of subject s will be included to allow for a minimum of 24 subject s (ant icipate up to 15% 
drop out rate, 24+4) to successfully complete the study. If the parallel -arm design is used, we will increase 
this to 25 per arm (50 total subjects); for more details on this, please refer to the section on Planned Interim 
Analyses:  9.4. 6. 
 
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of Sponsor.                                                                Page 44 of 70  These sample size tables are applicable to both the parallel -group design and the cross -over (paired or 
repeated -measures) design.  This is because we had no information with which to estimate the correlation  
among pairs of measures, so we used 0 corre lation.  This is the same as independent treatment groups, or 
parallel -arm design.  Using the largest sample size of the 3 tests, a cross -over design requires 23 subject s with 
endpoints and a parallel -arm design requires 23 subject s in each arm. Because we  prefer that each order in 
a cross -over design have the same number of subject s, we increased it to 24.  (Then the sample sizes were 
inflated for losses to follow -up, withdrawals, etc.)  
 
  

SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of WSAUD                                                                Page 45 of 70  
  
9.3 POPULATIONS FOR ANALYSES  
The following populations will be used in the analyses of the Primary and Secondary endpoints in this 
study.  
ITT Population : The intent to treat (ITT) population includes all subject s who received at least one 
hearing aid fitting strategy ( Vibe SF  or HCP fit ) to evaluate. This population will be used for the Primary 
Objective hypothesis test.  Missing values will be handled as de scribed i n Section 9.1.2.  
mITT Population : The modified intent to treat (mITT) population includ es all subject s in ITT population 
who have an endpoint for the analysis in question.  The mITT population will be used for the analysis of 
the Secondary Objectives. No imputation of missing values will be done for these endpoints.  
9.4 STATISTICAL ANALYSES  
 
9.4.1  GENERAL APPROACH  
 
Section 9 constitutes the statistical analysis plan (SAP) for this study.  
 
The overall approach to this study is that it is an adaptive design with the adaptation being a change 
from a cross -over design to a parallel -arm design if the lat ter is necessary to avoid the interaction  effects 
possible in a cross -over design.  The high -level design with adaptation is:  
 
1. The study begins with an intended sample size of 24  (28) subject s in a randomized cross -over 
design of SF first or HCP fit  first.  There is a washout period of 5 days intended to mitigate the 
order effect of the cross -over.  
2. After 12 subject s have completed both hearing aid fittings and both Field tests , we will test for 
the order effect by looking for a significant interaction t erm in the analysis.   (The methods of 
analysis are described below.)  
a. If there is no interaction effect, then we continue with the cross -over design.  
b. If there IS an interaction e ffect, then we will add subject s so that we have  a minimum of 
23 per arm  (23+2, to account for drop -outs) .  (Note that we don’t need 24 to balance 
the groups like we did in the cross -over design.)   The new subject s will be randomized to 
SF or HCP fit  for one period only .  They don’t cross over.   Of th e 12 existing subject s, we  
use only their Period 1 data;  we ignore their data post cross -over.  
 
NOTE:   We will not suspend the trial while we analyze the data from the first 12.   We will continue the 
cross -over study, but if we change to the parallel -arm d esign, we will ignore the Period 2 data  (i.e., Field 
Test 2  data ). 
 
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of WSAUD                                                                Page 46 of 70  
  
9.4.1.1  DESCRIPTIVE STATISTICS  
This section describes the descriptive statistics that will be provided with each analysis.  The statistics 
depend on the type of variable (endpoint) that is analyzed.  All secondary objectives involve descriptive 
analyses only.  
Descriptive statistics of subject  demographics and baseline hearing status will be tabulated.  No 
comparisons will be made because the same subject s serve as Vibe SF  strategy and HCP fit  strategy 
subjects in this cross -over study.   
The descriptive statistics that will be presented will depend on the data type:  
1) Continuous data will be summarized using n, mean, SD, minimum and maximum values.  
2) Categorical data will be summarized using frequency and perce ntage.  
3) Time -to-event data will be summarized using percentages at relevant time points, along 
with effective sample size and the 95% confidence interval.  
4) Frequency (count) data will be summarized as a categorical variable if there are 5 or 
fewer values (se e #2), or as a continuous variable if there are more than 5 distinct values 
(see #1).  
 
9.4.1.2  CONTROL OF TYPE 1 ERROR   
All hypothesis tests (of which there is only one compound test in this study, and that is for the Primary  
Effectiveness  Objective) will be conducted at α=0.05.  Non -inferiority tests (the type of test in this study) 
are by nature one -tailed.  The Primary hypothesis test will be conducted in 3 parts, as described in 
Section 9.1.1 . To control Type 1 error associated with mul tiple tests, all 3 tests for the Primary Objective 
must have a p -value of 0.05 or smaller  simultaneously . 
Although the Secondary Objectives do not include any hypothesis testing, they will not be analyzed or 
reported unless the primary hypotheses pass ( reject all 3 Hos).  
  
9.4.1.3  IMPUTATION OF MISSING DATA AND SENSITIVITY ANALYSES  
All attempts will be made to minimize missing data. However, if any subject s in the ITT population have 
missing primary endpoints, five (5) multiple imputations will be used for the analyses. This consists of 
imputing values for each missing value as a set (generating 5 -sets), analyzing the results for each set, 
and then pooling the results.  The Primary Effectiveness Endpoint is continuous, so the imputation 
method will be a multiple  linear regression using treatment assignment and baseline characteristics.  
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of WSAUD                                                                Page 47 of 70  
 A sensitivity analysis of the Primary Effectiveness Endpoint will be conducted as a tipping -point analysis, 
to examine the impact of missing data. It will only be conducted if the hypothesis test passes (i.e., 
rejects H o). We will start by assuming that all missing Primary Effectiveness Endpoints have values 
indicating the inferiority of Vibe SF  strategy, and if the Primary Effectiveness Hypothesis is not passed, 
we will chan ge one missing endpoint to a difference of 0 until the hypothesis passes.  This will enable 
determinat ion of the amount of missing data that would alter the final result on the primary 
effectiveness endpoint.  
If the hypothesis test of the Primary Effectiveness En dpoint does not pass, the hypothesis test will be 
repeated using only those subject s without major protocol violations , i.e., the mITT population . This test 
is for SPONSOR ´s information only, and  will not be used to support the study objective.  
 
9.4.1.4  RANDOMIZATION AND BLINDING  
 
At the time of the visit on which the subject  is provided with his/her first hearing aid, he/she will be 
randomized to either:  Vibe SF First/ HCP fit  Second or t o HCP fit  First /Vibe SF Second.  A computer -
generated pseudo -random -number list will be used for assigning the treatment order.  Assignments will 
be made either  by sealed envelope or provided real -time on the sponsor’s EDC website on a protected 
page.  
 
9.4.2  ANALYSIS OF THE PRIMARY EFFECTIVENESS ENDPOINT  
The mechanism for validating the Vibe SF  strategy will be the comparison of subject ´s hearing aid benefit 
as measure d by the change from each of the three APHAB communication subscales (EC, BN, RV) benefit 
score  (benefit score = unaided – aided)  when the hearing aids are HCP fit  compared to when it is Vibe SF  
by th e subject .     
There are 3 APHAB communication subscales that contribute to the perceived benefit (response 
condition), and each subscale benefit (EC, BN, RV) must simultaneously demonstrate the non -inferiority 
of Vibe SF  strategy to HCP fit  strategy.  Note that higher m eans are worse  (i.e., higher differences mean 
that Vibe SF  strategy performed worse ). 
• Ho EC(benefit):  ∆EC(benefit) HCP fit  - ∆EC(benefit) SF > 26     vs      
Ha EC(benefit):  ∆EC(benefit) HCP fit  - ∆EC(benefit) SF < 26  
• Ho BN(benefit): ∆BN(benefit) HCP fit  - ∆BN(ben efit) SF > 27     vs      
Ha BN(benefit): ∆BN(benefit) HCP fit  - ∆BN(benefit) SF < 27  
• Ho RV(benefit): ∆RV(benefit) HCP fit  - ∆RV(benefit) SF > 28     vs      
Ha RV(benefit): ∆RV(benefit) HCP fit  - ∆RV(benefit) SF < 28  
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of WSAUD                                                                Page 48 of 70  
 These are non -inferiority tests com paring the subject ´s perceived hearing aid benefit as measured by 
the difference in each of the three APHAB communication benefit subscales when the hearing aid is HCP 
fit compared to when it is Vibe SF  by the subject .  The NIM depends on the communication benefit 
subscale, according to Cox  (1995) , and these are the minimum  clinically important differences on each 
of the three communication benefit subscales.  
Note that because of the adaptive design which entails possibly moving from a cross -over design to a 
parallel -arm design, the analysis methods must differ slightly.  Section 9.4.2.1 describes the analysis we 
will use for a cross -over design.  Section 9.4.2.2 describes how we will use the cross -over analysis for the 
interim analysis to determine if we must adapt the design.  Section 9.4.2.3 describes the analysis we will 
use for a parallel -arm design if we change the design.  
9.4.2.1  ANALYSIS OF CROSS -OVER DESIGN DATA  
This is the final analysis that will be  used if the cross -over design is maintained throughout the study.  
Each communication benefit subscale will be analyzed using a repeated -measures analysis of variance 
(rm-ANOVA) in which the repeated (within) factors are order ( HCP fit  first or Vibe SF  first) and treat ment 
(HCP fit  or Vibe SF ); there are no between -group factors. The interaction term, order x treatment, will 
not be included because, if we use this design, it is because we have concluded that the interaction term 
is not significant.  See  Section 9.4.2.2.  
The hypothesis test for each communication benefit subscale will be conducted as the one -sided upper 
95% confidence bound of the regression coefficient on treatment. If this value is less than the NIM for 
that communication benefit subsca le, the null hypothesis will be rejected (at α=0.05, by definition of the 
confidence bound).  The p -values for all 3 communication subscales must be 0.05 or smaller in order for 
the global hypothesis test to pass (reject the global null of inferiority).  
Because Sponsor  would like to report a global p -value for these tests, the  3 p-values will be combined 
into a single value using the weighted harmonic mean (WHM) (Good, 1958)  (Wilson, 2019)  (Vovk & 
Wang, 2019) : 
pWHM = ∑ wi / ∑ (wi / pi)        i=1….L  
where L= 3, the number of order tests being combined into one subscale score.  The weights (w i ) are set 
equal to 0.3333…  They are weighted  equally because the scores are calculated with each component 
weighted equally. This method does not require the independence of the tests.  Although this method 
can be anticonservative, it has been shown to be very close to the intended false positive ra te when the 
pWHM is close to 0.05.  Since the sample was sized for this p -value, the pWHM should be neither 
conservative nor anti -conservative.  
Descriptive statistics for  the treatment groups for each of the three communication benefit subscales, 
EC(benefi t), RV(benefit), BN(benefit), at each time point will also be reported.  
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of WSAUD                                                                Page 49 of 70  
 9.4.2.2  INTERIM ANALYSIS OF CROSS -OVER DESIGN FOR DETERMINATION OF DESIGN 
APPLICATION  
An interim analysis will be conducted to determine if the design will be changed from a cross -over to a 
parallel -arm design.  The analysis will be conducted by an independent statistical group so that no 
information about the effects of fitting (SF vs HCP FIT ) will be known to Sponsor .  A nuisance parameter 
will be estimated and tested  for significance to decide whether to change the design.  
The analysis will be conducted as follows.  
Each communication benefit subscale will be analyzed using a repeated -measures analysis of variance 
(rm-ANOVA) in which the repeated (within) factors are o rder ( HCP fit  first or SF first) and treatment ( HCP 
fit or SF); there ar e no between -group factors. The interaction term, order x treatment, will be included 
to determine whether it is necessary to change from a cross -over design to a parallel -arm design.  This is 
the nuisance factor that is the crux of the adaptation. The presence of an interaction term means that 
the difference in benefit (i.e., the treatment effect) differs by order.  In this case, we cannot combine the 
estimate of HCP FIT -first benefit with HCP fit -second, and similarly for SF -first and second.   Here is the 
visua l representation of the effects  in the following Figures a, b and c : 
a) Treatment (TX) Effect        b)    TX, Order Effects                                  c)   TX, Order, Interact ion Effects  
        
HCPF = HCP fit  
 
Figure (a) shows an effect of treatment only.  The score with SF, averaged over SF First and SF Second , is 
different from the average score of HCP fit.  The scores for SF are the same for both orders, and that is 
also true for HCP fit, so there is no or der effect.  The difference between SF and HCP fit is the same for 
both orders, so there is no intera ction effect.  
 
Figure (b) shows an effect of treatment and of order.  The average SF score is lower than the average 
HCP fit score, and the averages are lo wer when SF is first than when HCP fit is first.  However, the 
difference between SF and HCP fit is the same  regardless of order, which means there is no intera ction 
effect. So, in spite of the order effect, it is possible to estimate the difference between treatments  and to 
test for the non -inferiority of SF to HCP fit . 
 
Figure (c) shows an effect of treatment and order, and also an interaction effect.  The inte raction effect 
occurs because the difference between treatments is not the same with both orders.  Compare this to 
Figure (b), in which the difference is the same.  In this case, the test for non -inferiority of SF to HCP fit 

SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of WSAUD                                                                Page 50 of 70  
 must be done on SF First and HCP fit First separately b ecause non -inferiority might be true in one case 
and not in the other.  
It is important to note that it is not the order effect, but the interaction effect, that makes it impossible 
to do a non -inferior ity test.  The interaction term will be tested be combining the p -values from the 3 
scales.  The method WHM, show in Section 9.4.2.1, will be used here, but in this case, it will be the 
interaction term p -values that are combined. The combined p -value will  be compared to α=0.10; if the 
null hypothesis of no interaction is rejected in favor of the hypothesis of an interaction, we will switch to 
the parallel -arm design.   
If the design is switched to parallel -arm, then subject s who have not crossed over will have only one 
treatment, and subject s who have crossed over will have only their first treatment used in the analysis 
of the parallel -arm data.  See Section 9.4.2.3.  
9.4.2.3  ANALYSIS OF PARALLEL -ARM DESI GN DATA  
Each communication benefit subscale will be analyzed using a t -test of the benefit with SF (as described 
previously, the difference between baseline and SF score) versus the benefit with HCP fit (the difference 
between ba seline and HCP fit score).  The p -values fo r all 3 communication subscales must be 0.05 or 
smaller in order for the global hypothesis test to pass (reject the global null of inferiority).  
 
Because Sponsor  would like to report a global p -value for these tests, the 3  p-values will be combined 
into a single value using the method of WHM as described as in Section 9.4.2.1.  The p -values cannot be 
assumed to be independent because the data are from the same set  of subject s, and it is therefore likely 
that the benefit on the E C score is correlated with the benefit on the RV score, etc.  
Descriptive statistics for the treatment groups for each of the three communication benefit subscales, 
EC(benefit), RV(benefit), BN(benefit), at each time point will also be reported.  
 
9.4.3  ANALYSIS OF THE SECONDARY ENDPOINTS  
Descriptive statistics will be reported on each endpoint by fitting strategy and overall, according to the 
list in Section 9.4.1.1. In addition, some endpoints require more detailed description.  Additional 
descriptive statistics that will be reported are listed with the endpoints.  
EMA Scores : Descriptive statistics of the scores will be reported by fitting strategy and measurement 
time for each real -life condition.  
QuickSIN Scores : Descriptive statistics of the scores will be reported by fitting strategy and 
measurement time.  
SSQ-12 Scores : Descriptive statistics of the scores will be reported by fitting strategy and measurement 
time for each subscale.  
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of WSAUD                                                                Page 51 of 70  
 Gain Selection : Descriptive statistics of the probe -mic REM will be reported by fitting strategy and 
measurement time.  
Fitting Preference : Descriptive statistics of the scores will be reported by fitting strategy and 
measurement time.  
9.4.4  SAFETY ANALYSES  
It is very unlikely that any device -related adverse events (ADEs) will be reported during this NSR device 
study. However, those that are reported will be tabulated by severity (mild -moderate -severe), 
seriousness (serious or non -serious) and relatedness (relat ed, not related).  
9.4.5  BASELINE DESCRIPTIVE STATISTICS  
 
Descriptive statistics of patient demographics and baseline hearing status will be tabulated.  No 
comparisons will be made because the same subject s serve as Vibe SF and HCP fit  strategy groups  in this  
cross -over study .  The statistics that will be tabulated for each variable are listed by variable type in 
Section 9.4.1. 1. 
 
9.4.6  PLANNED INTERIM ANALYSES  
 
See Section 9.4.2.2.  We will conduct an interim analysis using a nuisance parameter to decide i f the 
design of the study will be changed from a cross -over design to a parallel -arm design.   
 
9.4.7  SUB -GROUP ANALYSES  
 
This study does not include any sub -group analyses.  
 
9.4.8  TABULATION OF INDIVIDUAL SUBJECT  DATA  
 
Data listings by subject  will be provided to regulatory agencies.  
 
 
10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  
 
10.1 REGULATORY, ETHICA L, AND STUDY OVERSIGHT CONSIDERATIONS  
 
10.1.1  INFORMED CONSENT PROCESS  
 
10.1.1.1  CONSENT/ASSENT AND OTHER INFORMATIONAL DOCUMENTS PROVIDED TO SUBJECT S 
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of WSAUD                                                                Page 52 of 70  
 The responsible investigator at each site ensures that approval  of advertisements used to recruit subject s 
and of the Patient Information / Informed consent form,  from an appropriately c onstituted IRB , is sought 
for the clinical investigation. The decision of the IRB concerning the conduct of the clinical investigation 
will be made in writing to the Spon sor and Investigator before commencement of this clinical 
investigation. The clinical investigation can only begin once approval has been received. Any additional 
requirements imposed shall be implemented.  
 
Consent forms , including all items as per ISO1455,  describing in detail the study intervention, st udy 
procedures, and risks are given to the subject  and written documentation of informed consent is 
required prior to starting intervention/administering study intervention.  The following consent 
materials a re submitted with this protocol:  
• Patient Information Sheet  
• Informed Consent Form  
 
The above listed documents are provided separately.  
 
10.1.1.2  CONSENT PROCEDURES AND DOCUMENTATION  
The screening process is described in detail in 8.1.1 Screening.  
If it is determin ed that mild -to-moderate hearing imp airment is present and that all inclusion criteria 
seem to be fulfilled the study subject  information will be provided and the subject  will be asked for their 
voluntary informed consent to participate in the clinical study.  
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in the clinical 
investigation and continues throughout the individual’s clin ical investigation participation.  Consent forms 
will be IRB -approved and the subject  will be asked to read and review the document.  
 
The investigator will obtain informed consent, as per 21 CFR 50, for each subject . The investigator will 
explain the resea rch clinical investigation to the subject  and answer any questions that may arise. A verbal 
explanation will be provided in terms suited to the subject ’s comprehension of the purposes, procedures, 
and potential risks of the clinical investigation and of th eir rights as research subject s.  Subject s will have 
the opportunity to carefully review the written consent form and ask questions prior to signing.  The 
subject s should have the opportunity to discuss the clinical investigation with their family or surrog ates 
or think about it prior to agreeing to participate.  
The subject  must also give their permission for representatives of the Sponsor, auditor  and regulatory 
authorities to review their hospital records for the purposes of source data verification.  
The subject  will sign the informed consent document prior to any procedures being done specifically for 
the clinical investigation. Subject s must be informed that participation is voluntary and that they may 
withdraw from the clinical investigation at any time, without prejudice.  A copy of the informed consent 
document will be given to the subject s for their records. The informed consent process will b e conducted 
and documented in the source document (including the date), and the form signed, before the subject  
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of WSAUD                                                                Page 53 of 70  
 undergoes any clinical investigation -specific procedures. The rights and welfare of the subject s will be 
protected by emphasizing to them that t he quality of their medical care will not be adversely affected if 
they decline to participate in this clinical investigation.  
10.1.2  STUDY DISCONTINUATION AND CLOSURE  
 
This clinical investigation may be temporarily suspended or prematurely terminated if there is  sufficient 
reasonable cause.  Written notification, documenting the reason for clinical investigation suspension or 
termination, will be provided by the suspending or terminating party to the IRB and regulatory authorities. 
If the clinical investigation i s prematurely terminated or suspended, the Principal Investigator (PI) will 
promptly inform clinical investigation subject s who will also be informed of changes to clinical 
investigation visit schedule.  
 
 Circumstances that may warrant termination or suspension include, but are not limited to:  
• Ethical concerns  
• Insufficient subject  recruitment  
• Alterations in accepted clinical practice that make the continuation of a clinical trial unwise.  
• Determination of unexpected, significant, or unacceptable risk to subject s 
• Demonstration of efficacy that would warrant stopping    
• Insufficient compliance to  Clinical Investigation Plan requirements  
• Data that are not sufficiently complete and/or evaluable  
• Determination that the primary endpoint has been met  
• Determination of futility  
 
Clinical investigation may resume once concerns about safety, Clinical Invest igation Plan compliance, and 
data quality are addressed, and satisfy the sponsor, the IRB and the regulatory authorities.  
 
Should termination occur, the procedures will be arranged on an individual basis after review and 
consultation by both parties. In t erminating the clinical investigation, the Sponsor and the Principal 
investigator will assure that adequate consideration is given to the protection of the subject ’s interests.  
 
10.1.3  CONFIDENT IALITY AND PRIVACY  
 
Subject  confidentiality and privacy is strictly held in trust by the participating investigators, their staff, and 
the sponsor(s) and their interventions. Therefore, the clinical investigation plan, documentation, data, 
and all other information generated will be held in strict confidence. No information concerning the 
clinical investigation or the data will be released to any unauthorized third party without prior written 
approval of the sponsor.  
All research activities will be conducted in as private a setting as possible.  
 
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of WSAUD                                                                Page 54 of 70  
 The clinical investigation monitor, other authorized representatives of the sponsor, representatives of the 
IRB, regulatory agencies or the company supplying the clinical investi gation product may inspect all 
documents and records required to be maintained by the investigator, including but not limited to, 
medical records (office, clinic, or hospital) and pharmacy records for the subject s in this clinical 
investigation. The clinic al investigation site will permit access to such records.  
 
The clinical investigation subject ’s contact information will be securely stored at each clinical site for 
internal use during the clinical investigation. At the end of the clinical investigation, all records will 
continue to be kept in a secure location for as long a period as dictated by the reviewing IRB, or sponsor 
requirements.  
Clinical investigation subject  research data, which is for purposes of statistical analysis and scienti fic 
reporting, will be entered in an Electronic Data Capture (EDC) system database. The data entered will not 
include the subject ’s contact or identifying information. Rather, individual subject s and their research data 
will be identified by a unique clini cal investigation identification number. The clinical investigation data 
entry and clinical investigation management systems used will be secured and password protected.  
 
10.1.4  KEY ROLES  AND STUDY GOVERNANCE  
 
Principal Investigator  Independent Medical Monitor  
Name, degree, title  Name, degree, title  
Institution Name  Institution Name  
Address  Address  
Phone Number  Phone Number  
Email  Email  
Further information in regards to  members of the study team roles and responsibilities can be found in 
the study monitoring plan.  
10.1.5  SAFETY OVERSIGHT  
Safety oversight will be under the direction of the Independent  Medical Monitor. All adverse event 
reports will be directed to the Sponsor / the Independent Medical Monitor. The Independent Medical 
Monitor will be responsible for the timely review of all adverse events in order to identify seriousness, 
severity, causality and expectedn ess (anticipated vs. unanticipated) of the event to the study device 
and/or study procedure.   
The Independent Medical Monitor will review all adverse events throughout the duration of the 
study until study completion.  
10.1.6  CLINICAL MONITORING  
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of WSAUD                                                                Page 55 of 70  
 The Sponsor shal l secure compliance with the requirements of § 812.46 with respect to monitoring 
investigations. Clinical site monitoring is conducted to ensure that the rights and well -being of trial 
subject s are protected, that the reported trial data are accurate, comp lete, and verifiable, and that the 
conduct of the trial is in compliance with the currently approved clinical investigation plan/amendment(s), 
with the ISO 14155 and with any other applicable regulatory requirement(s).  
 
• Monitoring for this study will be performed by delegee.  
• Monitoring will be performed on -site as well as remote. After the Site initiation visit, up to 5 
monitoring visits are planned  during the study. Due to the setup of the study, with an interaction 
effect assessment after 1 2 subject s to decide on a final sample size, monitoring will be planned 
accordingly to make sure that the data needed has been reviewed before assessment.  In case of 
difficulties to perform on -site monitoring, this data can be reviewed centrally / remotely.  
• Risk-based monitoring will be used, including targeted data verification of key data variables :  
o Informed consent  
o Adherence to eligibility criteria  
o Device accountability  
o Primary endpoints  
o Safety endpoints  
o In addition to this a random review of certain data will be pe rformed.  
• In addition to on -site monitoring, the following alternative monitoring techniques will be used:  
o Centralized monitoring by data manager / clinical monitor  
o Communication with study site staff   
• Details of clinical site monitoring are documented in a Clinical Monitoring Plan (CMP). The CMP 
describes in detail who will conduct the monitoring, at what frequency monitoring will be done, 
at what level of detail monitoring will be performed, and the distribution of monitoring reports.  
 
10.1.7  QUALI TY ASSURANCE AND QUALITY CONTROL  
The clinical site will perform internal quality management of clinical investigation conduct, data 
collection, documentation and completion.   
Quality control (QC) procedures will be implemented beginning with the data entr y system and data QC 
checks that will be run on the database will be generated. Any missing data or data anomalies will be 
communicated to the site(s) for clarification/resolution.  
Following written Standard Operating Procedures (SOPs), the monitors will v erify that the clinical trial is 
conducted and data are generated and biological specimens are collected, documented (recorded), and 
reported in compliance with the clinical investigation plan, ISO 14155, and any other applicable 
regulatory requirements.  
 
The investigational site will provide direct access to all trial related sites, source data/documents, and 
reports for the purpose of monitoring and auditing by the sponsor, and inspection by local and 
regulatory authorities.  
 
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of WSAUD                                                                Page 56 of 70  
 Quality control procedures shall ensure that participating investigators maintain the records of each 
subject ’s case history and exposure to the device under §812.140(a)(3)(i) and ensure that participating 
investigators make the following required reports to the sponsor:  
• Unanticipated Adverse Device Effects [§812.150(a)(1)]  
• Withdrawal of IRB Approval [§812.150(a)(2)]  
• Failure to obtain informed consent [§812.150(a)(5)]  
• Other reports requested by a reviewing IRB or FDA [§812.150(a)(7)]  
 
As per 21 C RF §812. 45, a sponsor who discovers that an investigator is not complying with the signed 
agreement, the investigational plan, the IDE requirements, any other applicable FDA regulations, or any 
conditions of approval imposed by the reviewing IRB or FDA must prompt ly either secure compliance, or 
discontinue shipments of the device to the investigator and terminate the investigator's participation in 
the investigation. A sponsor must also require that the investigator dispose of or return the device, 
unless this acti on would jeopardize the rights, safety, or welfare of a subject.  
The following sponsor records will be maintained in one location and available for FDA inspection 
[§812.140(b)(4)]:  
• the name and intended use of the device;  
• the objectives of the investigation;  
• a brief explanation of why the device is not a significant risk device;  
• the name and address of each investigator;  
• the name and address of each IRB;  
• a statement of the extent to which the good manufacturing practices (21 CFR 820) will be 
followed in manufacturing the device.  
• any other information required by FDA  
The sponsor will maintain records conc erning complaints and adverse device effects whether 
anticipated or not [§812.140(b)(5)].  
The sponsor will provide the following reports in a timely manner to FDA, the IRB's, and/or the 
investigators [§812.150(b) (1) through (3) and (5) through (10)].  
• Unanticipated Adverse Device Effects  
• Withdrawal of IRB Approval  
• Withdrawal of FDA Approval  
• Progress Reports  
• Recalls and Device Disposition  
• Final Report  
• Failure to obtain informed consent  
• Significant Risk Device Determination  
• Other Reports  
 
 
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of WSAUD                                                                Page 57 of 70  
 10.1.8  DATA  HANDLING  AND RECORD  KEEPING   
 
10.1.8.1  DATA COLLECTION AND  MANAGEMENT RESPONSIBILITIES  
Data collection is the responsi bility of the clinical trial staff at the site under the supervision of the site 
investigator. The investigator is responsible for ensuring the accuracy, completeness, legibility, and 
timeliness of the data reported.  
 
All source documents should be completed in a neat, legible manner to ensure accurate inter pretation 
of data.   
 
Study visit worksheets / checklists will be provided for use as support ing source document for recording 
data for each subject  enrolled in the study.  Data recorded in the electronic case report form (eCRF) 
derived from source documents should be consistent with the data recorded on the source documents.  
 
An Electronic Data Capture system will be used, created as per clinical in vestigation requirements. The 
database will be tested to verify that the design meets the specification. Data validation checks will be 
designed to be applied consistently across trial data, and all errors that are identified through data 
validation checks  should be corrected with a documentation of the discrepancy resolution.   
Clinical data (including adverse events (AEs), and expected adverse reactions data) will be entered into 
SMARTTRIAL, a 21 CFR Part 11 -compliant data capture system provided by the S ponsor. The data system 
includes password protection and internal quality checks, such as automatic range checks, to identify 
data that appear inconsistent, incomplete, or inaccurate. Clinical data will be entered directly from the 
source documents.  
 
Valid ation of the system will be performed to ensure that data entered map to the correct variable in 
the system, and that the parameters for the variable correctly store the data.  
Further details can be found in the clinical investigation Data Management Plan . 
10.1.8.1.1  DATA  MANAG EMENT SYSTEM   
 
SMART -TRIAL will be used as the primary Electronic Data Capture tool in this study. SMART -TRIAL is 
developed and owned by MEDEI ApS ( www.medei.dk ). 
Development, validation, and maintenance of SMART -TRIAL is conducted acc ording to medical device 
software and quality standards.  
 
The Sponsor will enter a contractual agreement with MEDEI ApS which clarifies how MEDEI ApS 
complies with regulatory requirements for processing of personal identifiable information according to 
applicable regulations.  
All critical actions performed by users of SMART -TRIAL are logged both in relation to general operations 
(e.g. user creation/edit) and study specific operations. Audit logging ensures that all operations 
performed by users can be trac ed. 
Validation of the system will be performed before it is being released.  
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of WSAUD                                                                Page 58 of 70  
 10.1.8.2  DATA SECURITY, ACCESS AND BACK -UP  
All data in SMART -TRIAL  is collected, transferred, and stored encrypted in databases, which are hosted 
on ISO certified servers that are managed  by MEDEI ApS  within the European Union (Ireland). Backups 
are performed continuously throughout the day and stored within the same country.  
 
To collect and view data, or access a study in SMART -TRIAL users must create a user account with an 
associated st rong password, which shall be used to authenticate with the system. To perform any 
security critical actions within the system, a user must be authenticated. SMART -TRIAL implements two -
step authentication for every log in, i.e. users must log in to the sys tem using their created credentials 
and confirm their authentication with a unique one -time code sent to their mobile phone or e -mail 
address. On successful authentication, SMART -TRIAL creates a unique user -session that is used to 
identify the authenticate d user.  
10.1.8.3  ANALYSIS AND ARCHIVING  
 
After a proper quality check and assurance, the final data validation is run. If there are no discrepancies, 
the Statistical datasets are finalized in consultation with the statistician. Once approval for locking is 
obtained from all stakeholders, the data base is locked and clean data is extracted for statistical analysis. 
After the database is locked, no modification in the database is possible except in exceptional cases.  
 
An unlocking of the database requires proper documentation and an audit trail has to be maintained 
with sufficient justification for updating the locked database. Data extraction is done from the final 
database after locking. This is followed by its archiv al. 
10.1.8.3.1  ELECTRONIC AND CENTRAL  DATA VALIDATION  
 
Data validation will be completed on a regular basis. Quality control audits of all key performance and 
safety data in the database will be made after the sites complete enrolment. The entire database will be 
re-validated to ensure that there are no outstanding data discrepancies prior to database lock. Any 
changes to the database after that time will require joint written agreement between Clinical Affairs  and 
Clinical Data Management. Concomitant Medications an d Adverse Events entered into the database will 
be reviewed and assigned the appropriate codes by qualified personnel.  
 
10.1.8.4  STUDY RECORDS RETENTION  
The Investigator will be responsible for data handling and record keeping and retention. Data required 
accordin g to this Clinical Investigation Plan must be recorded on the electronic case report forms (eCRFs) 
as soon as possible.  
If the Investigator relocates, or for any reason withdraws from the clinical investigation, the Sponsor 
should be prospectively notifie d. Subjects' hospital files will be archived according to local regulations.  
 
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of WSAUD                                                                Page 59 of 70  
 Study documents should be retained for a minimum of 2 years after the date the investigation is 
completed or terminated or the records are no longer required to support a PMA or PDP, whichever 
dates is longer.  These documents should be retained for a longer period, however, if required by local 
regulations. No records will be destroyed without the written consent of the sponsor, if applicable. It is 
the responsibility of the sponsor to inform the investigator when these documents no longer need to be 
retained.  
 
10.1.9  PROTOCOL DEVIATIONS  
 
A protocol deviation is any noncompliance with the clinical trial protocol  and the ISO 14155 
requirements. The noncompliance may be either on the part of the subject , the investigator, or the 
study site staff. As a result of deviations, corrective actions are to be developed by the site and 
implem ented promptly.  
An investigator shall notify the sponsor and the reviewing IRB of any deviation from the investigational 
plan to protect the life or physical well -being of a subject in an emergency. Such notice shall be given as 
soon as possible, but in no event later than 5 working days after the emergency occurred. Except in such 
an emergency, prior approval by the sponsor is required for changes in or deviations from a plan, and if 
these changes or deviations may affect the scientific soundness of the plan or the rights, safety, or 
welfare of human subjects, FDA and IRB is also required.  
 
It is the responsibility of the sit e investigator to use continuous vigilance to identify and report 
deviations . All deviations must be addressed in study source documents, and reported to the Sponsor .  
Protocol deviations must be sent to the reviewing Institutional Review Board (IRB) per t heir policies. The 
site investigator is responsible for knowing and adhering t o the reviewing IRB requirements.  
Further details about the handling of protocol deviations will be included in the Clinical Monitoring Plan .  
 
10.1.10  CONFLICT OF  INTEREST  POLICY  
 
The independence of this study from any actual or perceived influence, such as by the medical device 
industry, is critical.  Therefore, any actual conflict of interest of persons who have a role in the design, 
conduct, analysis, publication, or any aspect of this trial will be disclosed and managed. Furthermore, 
persons who have a perceived conflict of interest will be required to have such conflicts managed in a 
way that is appropriate to their participation in the design and conduct of this trial.  The st udy 
leadership has established policies and procedures for all study group members to disclose all conflicts 
of interest and will establish a mechanism for the management of all reported dualities of interest.  
 
10.2 ADDITIONAL CONSIDERATIONS  
 
There is currently an outbreak of respiratory disease caused by a novel coronavirus, which may impact 
the conduct of clinical trials of medical products. Challenges may arise, for example, from quarantines, 
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of WSAUD                                                                Page 60 of 70  
 site closures, travel limitations, interruptions to the supply chain for the investigational product or other 
considerations if site personnel or trial subject s become infected with COVID -19. These challenges may 
lead to difficulties in meeting protocol -specified procedures, including administering or us ing the 
investigational product or adhering to protocol -mandated visits and testing, leading to unavoidable 
protocol deviations.  
 
Ensuring the safety of trial subject s is paramount. It may be necessary to modify the study conduct due 
to changing circumsta nces. This may include changes to t rial recruitment, continuing use of the 
investigational product for patients already participating in the trial, and the need to change patient 
monitoring during the trial. In all cases, it is critical that trial subject s are kept informed of changes to 
the study and monitoring plans that could impact them.  
 
The Sponsor, in consultation with clinical investigators and Institutional Review Boards (IRBs) may 
determine that the protection of a subject ’s safety, welfare, and rights is best served by continuing a 
study subject  in the trial as per the protocol or by discontinuing the administration or use of the 
investigational product or even participation in the trial.  
Due to the fact that the device is a non -significant risk  device, with no or very limited expected Adverse 
Events, no increased risk to safety is expected in the case that the patient cannot come bac k for a 
planned follow up visit.  
 
  
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of WSAUD                                                                Page 61 of 70  
  
10.3 ABBREVIATIONS  
 
Abbreviation  Word  
AE Adverse Event  
APHAB  Abbreviated Profile of Hearing Aid Benefit  
AV APHAB subscale: aversiveness of environmental sounds  
BN APHAB communication subscale: communication in settings with background noise  
CFR  Code of Federal Regulations  
EC APHAB communication subscale: ease of communication in favorable conditions  
EasyFit  EasyFit  web application  
EMA  Ecological Momentary Assessment  
GCP  Good Clinical Practice  
HCP  Hearing Care Professional  
HCP fit  Strategy  Silk 1X Hearing Care Professional Hearing Aid Fitting  Strategy  
Ha  Alternative hypothesis  
Ho Null hypothesis  
ICF Informed Consent Form  
IRB Institutional Review Board  
ISO International Organization for Standardization  
ITT Intent to Treat population  
mITT  Modified intent to treat population  
n Number; sum of subject s 
NAL NL2  National Acoustic Laboratories Nonlinear Version 2  
NIM  Non-inferiority margin  
NSR  Non-Significant Risk  
OSPL  Output sound pressure level  
QuickSIN  Quick Speech -in-Noise test  
REM  Real-ear measures  
rmANOVA  Repeated -measures analysis of variance  
RV APHAB communication subscale: communication in reverberant rooms such as classrooms  
SAE  Serious Adverse Event  
SAP  Statistical analysis plan  
SF Self-Fitting  
SF Strategy  Self-Fitting Hearing Aid Fitting Strategy  
SOA  Schedule of Activities  
SSQ-12 Speech, Spatial and Qualities of Hearing scale  
 
10.4 PROTOCOL  AMENDMENT  HISTORY  
The table below is intended to capture changes of IRB -approved versions of the protocol, including a 
description of the change and rationale. A Summary of Changes table for the current amendment is 
located in the Protocol Title Page.  
 
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of WSAUD                                                                Page 62 of 70  
 Version  Date  Description of Change  Brief Rationale  
    
    
    
    
    
    
    
    
    
    
    
 
  
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of WSAUD                                                                Page 63 of 70  
  
11 REFERENCES  
Benjamini, Y., & Hochberg , Y. (1995). Controlling the False Discovery Rate: A Practical and Powerful 
Approach to Multiple Testing. J.R. Statist. Soc. B, 57 (1), 289 -300. 
Carr, K. (2020, March 16). 20Q: Consumer Insights on Hearing Aids, PSAPs, OTC Devices, and More from 
MarkeTrak 10. AudiologyOnline. Retrieved from 
https://www.audiologyonline.com/articles/20q -understanding -today -s-consumers -26648  
Cox, R., & Alexander, G. (1995). The abbreviated profile of hearing aid benefit. Ear & Hearing, 16 (2), 176 -
186.  
Cox, R., & Alexander, G. (1995). The abbreviated profile of hearing aid benefit. Ear & Hearing, 16 (2), 176 -
186.  
Date Accessed: 2021JAN26. (Verison 2). Data Sheet Vibe Air (EN).  Source of product information: 
WSAUD A/S: Document No:  D00216771.  
Date Accessed: 2021JAN26. (Version 1). Data Sheet Silk X (EN).  Source of product information: WSAUD 
A/S: Document No: D00202451.  
Date Accessed: 2021JAN26. (Version 1). User Guide Quick Start Vibe Air Remote Fit (EN).  Source of 
Product Information: WSAUD A/S: Document No: D00220217.  
Date Accessed: 2021JAN26. (Version 1). User Guide Silk X (EN).  Source of product information: WSAUD 
A/S: Document No: D00203084.  
Date Accessed: 2021JAN26. (Version 2). User Guide Safety Man ual Remote Fit (EN).  Source of product 
information: WSAUD A/S: Document No: D00219451.  
Date Accessed: 2021JAN26. (Version 5). User Guide Safety USA.  Source of product information: WSAUD 
A/S: Document No: D00168097.  
DEN180026.  (2018, May 11). Retrieved from  accessdata fda: 
https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN180026.pdf  
Edwards, B. (2020, Feb). Emerging Technologies, Market Segments, and MarkeTrak 10 Insights in 
Hearing Health Technology. Semin Hear, 41 (1), 37 -54. 
Good, I. (1958). Significance  tests in parallel and in series. Journal of the American Statistical Association, 
53(284), 799 -813. doi:https://doi.org/10.1080%2F01621459.1958.10501480  
Leohler, J., & et al. (2017). Sensitivity and specificity of the abbreviated profile of hearingaid ben efit 
(APHAB). Eur Arch Otorhinolaryngol (274), 3593 -3598.  
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of WSAUD                                                                Page 64 of 70  
 Noble, W., Jensen, N., Naylor, G., Bhullar, N., & Akeroyd, M. (2013). A short form of the Speech, Spatial 
and Qualities of Hearing scale suitable for clinical use: The SSQ12. International Journal of  
Audiology, 52 (6), 409 -412.  
Sabin, A., Van Tasell, D., Rabinowitz, B., & Dhar , S. (2020). Validation of a self -fitting method for over -
the-counter hearing aids. Trends in Hearing (24), 1 -19. 
Schiffman, S., Stone, A., & Hufford, M. (2008). Ecological moment ary assessment. Annual Review of 
Clinical Psychology, 4 , 1-32. 
Vovk, V., & Wang, R. (2019, November 3). Combining p -values via averaging. On-line Compression 
Modelling Project (New Series): Working Paper #21 . Retrieved from 
http://alrw.net/articles/21.pdf  
Wilson, D. (2019). The harmonic mean p -value for combining dependent tests. Proceedings of the 
National Academy of Sciences USA, 116 (4), 1195 -1200. 
doi:https://doi.org/10.1073%2Fpnas.1814092116  
WSAudiology. (2020.11.24). Product Risk Assessment.  EasyFit system (covering HW and SW 
components). Retrieved Verion: 2.0 Doc. ID: D00212131  
Wu, Y., Stangl, E., Zhang, X., & Bentler, R. (2015). Construct validity of the Ecological Momentary 
Assessment in audiological research. J Am Acad Audiol, 26 (10), 872 -84. 
Yulia Carroll, J. E. (2017, February 10). Vital Signs: Noise -Induced Hearing Loss Among Adults - United 
States 2011 -2012. Morbidity and Mortality Weekly Report (MMWR).  
 
  
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of WSAUD                                                                Page 65 of 70  
 12 APPENDIX I NONSIGNIFICANT RISK DETERMINATION  
 
Nonsignificant Risk Device Study Classification  
US FDA Definition  
Non -significant risk devices are devices that do not pose a significant risk to the human subjects. Examples 
include most daily -wear contact lenses and lens solutions, ultrasonic dental scalers, Foley catheters, 
endoscopes, magnetic resonance imaging devic es, and low power lasers for treatment of pain.  
A non -significant risk device study requires only IRB approval prior to initiation of a clinical study. Sponsors 
of studies involving non -significant risk devices are not required to submit an IDE application to the FDA 
for approval. Submissions for non -significant risk device investigations are made directly to the IRB of each 
participating institution. Sponsors should present to the reviewing IRB an explanation  why the device does 
not pose a significant risk. If the IRB disagrees and determines that the d evice poses a significant risk, the 
sponsor must report this finding to the FDA within five working days [§812.150(b)(9)]. The FDA considers 
an investigation of a non -significant risk device to have an approved IDE when the IRB concurs with the 
non-signifi cant risk determination and approves the study . 
The sponsor also must comply with the abbreviated IDE requirements under  §812.2 (b) : 
• Labeling - The device must be labeled in accordance with the labeling provisions of the IDE regulations 
(§812.5 ) and must bear the statement "CAUTION  Investigati onal Device. Limited by Federal (or United 
States) law to investigational use.";  
• IRB Approval – The sponsor must obtain and maintain Investigational Review Board (IRB) approval 
throughout the investigation as a non -significant risk device study ; 
• Informed C onsent – The sponsor must assure that investigators obtain and document informed consent 
from each subject according to  21 CFR 50 , Protection of Human Subject s, unless documentation is 
waived by an IRB in accordance with §56.109(c);  
• Monitoring - All investigations must be properly monitored to protect the human subjects and assure 
compliance with approved protocols (§812.46). Guidance on monitoring investigations can be found in 
Guideline for the Monitoring of Clinical Investigations.  
• Records and Reports - Sponsors are required to maintain specific records and make certain reports as 
required by the IDE regulations.  
• Investigator Records and Reports – The sponsor must assure that part icipating investigators maintain 
records and make reports as required (see Responsibilities of Investigators); and  
• Prohibitions –Commercialization, promotion, test marketing, misrepresentation of an investigational 
device, and prolongation of the study are  prohibited ( §812.7 ). 
 
Background  
The Vibe Air is a n investigational  self-fitting air conduction hearing aid that is intended to compensate for 
impaired hearin g and incorporates technology, including software, that allows users to program 
independently their hearing aids. This technology integrates user input with a self -fitting strategy and 
enables users to independently derive and customize their hearing aid fitting and settings.  
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of WSAUD                                                                Page 66 of 70  
 Risk Assessment  
- Summary of test validation studies  
Document No: D00230228 Version 1, Clinical Study Doc – SF System Verification Activities Overview  
- SF System  
Risk assessment identified risks of over -ampli fication or misuse of the device, which are mitigated by 
design and labeling and are below risk acceptability threshold.  
Mitigations to prevent over -amplifications include a saf ety output limiter which is a hardware measure 
for limiting the  OSPL in failure mode. Hence, for the implemented cluster, the safety limiter is 6 dB above 
maximum OSPL of the specific cluster. Other mitigation measures include performance testing as 
electr oacoustics and software verification and validation.  Critical use -related scenarios (critical tasks) 
and essential functions have been identified and will be tested and validated in Human Factors testing.  
The risks associated with the use of the SF system  are acceptable when weighted against the ex pected 
benefits to the study subject s. The benefit outweighs the overall residual risk.  
- Comparison to Bose Hearing Aid  
 
The principles of operation, performance and repeatability of the self -fitting feature have been a subject 
of research for a number of years. In October 2018 , Bose  was granted its request for De Novo 
classification of the Bo se® Hearing Aid  (DEN180026, 2018) .  FD A classified this type of device as a Class Topic  Bose Hearing Aid 
(comparator device)  Vibe SF  (investigational 
device)  Risk comparison  
Energy source  Li-Ion rechargeable 
battery  Standard Zinc -Air hearing 
aid battery, non -
rechargeable  Lower risk due to the 
absence of a charging 
procedure  
Maximum output sound 
pressure level  115 dB SPL  114 dB SPL  No difference  
Frequency bandwidth  200 Hz to 8000 Hz  530 Hz to 840 0 Hz  No difference  
Acoustic coupling to ear 
canal  Closed  Open  Lower risk due to larger 
ventilation opening  
Noise reduction  Active noise cancellation 
(by inverse sound wave)  Noise reduction based on 
attenuation of the 
microphone signal  Lower risk due to the 
absence of high -level 
cancellation signals  
Directionality  Omnidirectional or 
directional hearing aid 
modes  User cannot control 
directionality  Lower risk due to 
reduced chance of not 
hearing vehicles, sirens, 
etc. 
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of WSAUD                                                                Page 67 of 70  
 II, self -fitting air -conduction hearing aid.  FDA created a new classification regulation (21 C.F.R. § 
874.3325) identifying this device type as a wearable sound amplifying device that is intended to 
compensate f or impaired hearing and incorporates technology, including software, that allows users to 
program their own hearing aids. This technology integrates user input with a self -fitting strate gy and 
enables users to independently derive and customize their heari ng aid fitting and settings.  
Comparison of Bose Validation Study vs. Vibe SF  Valid ation study depicted in the following table:   
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of WSAUD                                                                Page 68 of 70  
 Topic  Bose (comparator)  Vibe SF  (investigational 
device)  Risk  
Study design  2 arm study  Cross -over design  No new risk  
Study design  1 month field trial  2x 2 weeks field trial  No new risk, risk less 
because of scheduled 
visit after 2 weeks  
Experimental device  Prototype Hearing Aid 
with Earbuds and Neck 
band  Instant Fit CIC with Click 
Sleeves  Smaller risk than Bose  
because Vibe SF  based on 
a released hearing aid, 
SPONSOR  has a lot of 
experience with hearing 
aids 
Fitting device  Smartphone App  Smartphone Web App  For Vibe SF  risk of loss of  
internet connection  
Basis of First Fit  Start Setting at 0 dB real 
ear insertion gain,  
Adjustments with two 
wheels “Loudness” and 
“Fine -Tuning” inducing 
changes in 2 compression 
bands  Guided Procedure 
resulting to activation of 
one of the  built -in 
clusters  Similar risk than Bose , 
Vibe SF  clusters are based 
on audiological expertise, 
all settings after self -fit 
are audiologically valid.  
Loudnesswheel Settings 
of Bose  are also based on 
typical hearing aid 
settings  
Initial Setting  0 dB real  ear insertion 
gain  Most common Cluster 
activated  Smaller Risk than Bose 
because even in the case 
of failed first -fit, 
audiologically valid 
setting active in hearing 
aid 
Self-Fitting procedure  Adapting “Loudness” and 
“Fine -Tuning” Wheel on 
Smartphone App  Web -App guided 
procedure starting with 
hearing loss profiling and 
subsequent cluster and 
master gain selection. 
Overall loudness can be 
adapted before 
completing procedure  Smaller Risk because 
Hearing profiling gives 
some indication to 
heari ng condition, 
warnings are issued of 
hearing loss is too severe 
or asymm etrical  
Time of Self -Fitting  Over the course of the 
field -trial Completed at 1st visit 
Fine -tuning possible 
during field -trial Smaller Risk because 
subject  leaves clinic with 
the first fit completed, 
benefits from 
amplification straight 
away  
Questionnaires  APHAB , SSQ 12  APHAB , SSQ 12  No difference  
Speech Test  QuickSin  QuickSin  No difference  
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of WSAUD                                                                Page 69 of 70  
 The Bose Validation study reported no adverse events or serious adverse events during its study.  
 
Sources for all Risk information in this study protocol have been derived from the following documents:  
• Date Accessed 2021APR2 6. (Version X). EasyFit system covering hardware and software 
components  (EN). Source of product information: WSAUD A/S: Document No.: D00212131  
• Date Accessed 2021APR26. (Version X). Risk analysis for Hearing Instruments, Fitting -Software, 
Accessories and S martphone Apps (EN). Source of product information: WSAUD A/S: Document 
No.: D00013737  
• Date Accessed 2021APR26. (Version X). Self -Fitting System Risk Assessment for Clinical Study 
(EN). Source of product information: WSAUD A/S: Document No.:  PENDING  
 
Summary Conclusion  
The Vibe Air hearing aid  and SF study  poses a nonsignificant risk to patients when compared to other US 
FDA approved  SF hearing aid (Bose Hearing Aid)  and Bose validation study .  
  Surveys  5 Star Rating and in -the 
moment blinded 
comparisons of self -
selected settings with 
those that had been 
selected by audiologist  EMA Survey on Sound 
Quality, Speech 
understanding and 
Satisfaction  EMA Survey most likely 
quicker than having to 
compare two settings 
and giving a rating. Less 
disturbin g in every -day 
life 
Energy source  Li-Ion rechargeable 
battery  Standard Zinc -Air hearing 
aid battery, non -
rechargeable  Lower risk due to the 
absence of a charging 
procedure  
Maximum output sound 
pressure level  115 dB SPL  114 dB SPL  No difference  
Frequency bandwidth  200 Hz to 8000 Hz  530 Hz to 8400 Hz  No difference  
Acoustic coupling to ear 
canal  Closed  Open  Lower risk due to larger 
ventilation opening  
Noise reduction  Active noise cancellation 
(by inverse sound wave)  Noise reduction based on 
attenuation of the 
microphone signal  Lower risk due to the 
absence of high -level 
cancellation signals  
Directionality  Omnidirectional or 
directional hearing aid 
modes  User cannot control 
directionality  Lower risk due to 
reduced chance of not 
hearing vehic les, sirens, 
etc. 
SF Study   FINAL Version 1. 1 
Protocol #: D00232675   08 September  2021  
This document may not be shown to any unauthorized person without the express permission of WSAUD                                                                Page 70 of 70  
 13 APPENDIX  II DEVICE LABELING  
• Safety  and Maintenance  Information : Order/Item  No.: 10997498  Document No. 00473 -99T## -
#### ##, Master Rev 05, 04.2021 . (D00219154)  
• Quick Start Guide:  Order/Item  No.: 109975 11. Document No. 04477 -99T## -#### ##, Master Rev 
02, 04.2021  (D00219 293)  
• Quick Start Card: Document No.  Order/Item  No.: 21006310 , Master Rev01, 03.2021  
(D00229153)  
• Date Accessed 2021APR27. (Version X). SF Study Pa ckaging Image (EN). Source of information: 
WSAUD A/S: Document No.: D002 31203  
 
